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1  |  E XECUTIVE SUMMARY
Fetal growth restriction (FGR) is defined as the failure of the fetus 
to meet its growth potential due to a pathological factor, most com-
monly placental dysfunction. Worldwide, FGR is a leading cause of 
stillbirth, neonatal mortality, and short- and long-term morbidity. 
Ongoing advances in clinical care, especially in definitions, diagno-
sis, and management of FGR, require efforts to effectively trans-
late these changes to the wide range of obstetric care providers. 
This article highlights agreements based on current research in the 
diagnosis and management of FGR, and the areas that need more 
research to provide further clarification of recommendations.
The purpose of this article is to provide a comprehensive sum-
mary of available evidence along with practical recommendations 
concerning the care of pregnancies at risk of or complicated by FGR, 
with the overall goal to decrease the risk of stillbirth and neonatal 
mortality and morbidity associated with this condition. To achieve 
these goals, FIGO (the International Federation of Gynecology and 
Obstetrics) brought together international experts to review and 
summarize current knowledge of FGR.
This summary is directed at multiple stakeholders, including 
healthcare providers, healthcare delivery organizations and pro-
viders, FIGO member societies, and professional organizations. 
Recognizing the variation in the resources and expertise available 
for the management of FGR in different countries or regions, this 
article attempts to take into consideration the unique aspects of 
antenatal care in low-resource settings (labelled “LRS” in the recom-
mendations). This was achieved by collaboration with authors and 
FIGO member societies from low-resource settings such as India, 
Sub-Saharan Africa, the Middle East, and Latin America.
Aspects of FGR addressed in this article include prediction, 
diagnosis, investigation, management, and postpartum counsel-
ling. The main recommendations are given below and are sum-
marized in Table 1 (section 8) and in the management algorithms 
for high-resource settings (Figure 1a) and low-resource settings 
(Figure 1b) (section 4).






1. Women should undergo risk stratification for FGR (and other placenta-mediated complications) at the 
time of the first trimester antenatal visit using history-based (medical and obstetric) risk factors.
⊕⊕⊕○ Strong
2. There is no evidence to support the routine use of biochemical markers for the prediction of FGR. 
However, when such information is available as part of the prenatal genetic screening for trisomy 21, 
it may be reasonable to use this information for the purpose of risk stratification for FGR (and other 
placenta-mediated complications).
⊕⊕⊕○ Strong
3. Ultrasound-based markers and multiparameter algorithms have only a moderate predictive accuracy for 
FGR, and therefore currently cannot be recommended for universal screening.
⊕⊕⊕○ Strong
4. Women at high risk for FGR should undergo close surveillance of fetal growth starting at 24–28 weeks.
LRS  In low-resource settings, the frequency and type of monitoring may be limited by the availability 
of obstetric ultrasound.
⊕⊕⊕○ Strong
5. Women should be advised that smoking cessation and elimination of alcohol and illicit drugs can decrease 
the risk of FGR.
⊕⊕⊕○ Strong
6. Women should be advised on the association of insufficient gestational weight gain with FGR and be 
informed regarding their target weight gain range.
⊕⊕⊕○ Strong
7. There are insufficient data to recommend routine treatment with aspirin in all women at high risk of FGR. 
Treatment with aspirin at a dose of 100–150 mg starting at 12–16 weeks may be considered in selected 
cases such as women who are at high risk of pre-eclampsia or those with a history of placenta-mediated 
FGR.
⊕⊕○○ Weak
8. Low-molecular-weight heparin is not recommended for the prevention of FGR in women at high risk of 








1. Small for gestational age (SGA) is defined as an estimated fetal weight or birth weight below the 10th 
percentile for gestational age.
⊕⊕⊕⊕ Strong
2. The definition of fetal growth restriction (FGR) should be based on a combination of measures of fetal 
size percentile and Doppler abnormalities. We support the consensus-based definitions for early and late 
fetal growth restriction by Gordijn et al.1 as described in Box 1 (section 4.2.1).
 In low-resource settings, FGR may be defined in the same way as SGA (fetal weight or birth weight 
below the 10th percentile for gestational age).
⊕⊕○○ Strong
LRS
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1. Women with suspected FGR should undergo systematic assessment that includes the following: (1) detailed 
history; (2) detailed sonographic assessment for structural anomalies, soft markers, and sonographic signs 
related to fetal infection; (3) Doppler studies that include at least the umbilical artery and, when available, 
also the uterine and middle cerebral arteries; and (4) maternal screening for relevant congenital infections, 
which should be focused on cytomegalovirus and toxoplasmosis, but may also include rubella, herpes, 
syphilis, malaria, and Zika virus in cases at high risk.
LRS  The extent of investigation may be limited by available resources. Assessment should include 
screening for infections such as malaria and Zika virus in endemic areas.
⊕⊕⊕⊕ Strong
2. Confirmation of gestational age should be the first step when FGR is suspected. With the exception of 
pregnancies achieved by assisted reproductive technology, first-trimester crown–rump length is the most 
accurate method to date pregnancy when in the range of 7–60 mm. If more than one scan is performed in 
the first trimester, the earliest scan with a crown–rump length of at least 10 mm should be used.
LRS  In low-resource settings, dating may need to be based on menstrual history or symphysis–fundal height.
⊕⊕⊕⊕ Strong
3. Amniocentesis for karyotype (as well as microarray and polymerase chain reaction for infectious agents when 
available) should be offered to women with suspected FGR, especially in cases with early-onset severe (estimated 
fetal weight <3rd percentile) FGR, in the presence of sonographic findings associated with genetic or infectious 
etiologies, no obvious signs of placental dysfunction, and when the findings are likely to affect management.
LRS  The availability of genetic testing may be limited by available resources.
⊕⊕⊕○ Strong






1. Symphysis–fundal height is a simple and inexpensive tool that can be used as the primary screening 
strategy for FGR in low-risk pregnancies in both low- and high-resource settings.
⊕⊕⊕○ Strong
2. There is no evidence to support routine third-trimester ultrasound for the detection of FGR, as this practice 
has not been shown to be associated with improved perinatal outcomes.
⊕⊕⊕⊕ Strong
3. The choice of the equation used for sonographic fetal weight estimation may be based on validation within 
the local population. If this information is not available, we recommend that the following equation of 
Hadlock (based on head circumference [HC], abdominal circumference [AC], and femur length [FL]) should 
be used2: Log10 weight =1.326 – 0.00326*AC*FL + 0.0107*HC + 0.0438*AC + 0.158*FL
⊕⊕⊕○ Strong
4. Growth standards that are based on sonographic fetal weight estimation should be preferred over growth 
references and over charts that are based on birth weight.
⊕⊕⊕○ Strong
5. We support the recommendation of the FIGO Safe Motherhood and Newborn Health Committee that local 
or regional growth charts should be preferred over universal charts.3 Alternatively, universal standards 
may be used with locally adjusted thresholds to avoid under- or overdetection of FGR.
⊕⊕⊕○ Strong
6. The decision regarding which growth chart to use may be further guided by comparing the performance of 
the various charts in the population of interest, using local data sets.
⊕⊕○○ Weak
7. Based on the available evidence it seems reasonable to use twin-specific charts for the assessment of fetal 
growth in twin gestations, as this has the potential to avoid overdiagnosis of FGR in this population.
⊕⊕○○ Weak
8. In twin gestations, the diagnosis of FGR should also take into consideration intertwin size discordance, 
especially in the case of monochorionic placentation.
⊕⊕⊕⊕ Strong






1. Fetal movement counting is a simple and inexpensive tool that may decrease the risk of stillbirth in 
pregnancies with FGR in both high- and low-resource settings.
⊕⊕○○ Strong
2. Surveillance in pregnancies with FGR should follow a uniform protocol that is based on a combination 
of biophysical (cardiotocogram/nonstress test [CTG/NST], computerized fetal heart rate monitoring 
[cCTG], biophysical profile) and cardiovascular (umbilical artery and middle cerebral artery, with or 
without ductus venosus Doppler) parameters along with predetermined thresholds for delivery.
LRS  In low-resource settings, the combination of CTG/NST and umbilical artery Doppler provides 
sufficient accuracy for the detection of fetal deterioration.
⊕⊕⊕○ Strong
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3. In late-onset FGR, middle cerebral artery Doppler and the cerebroplacental ratio can provide additional 
information on fetal deterioration and should be included as part of the Doppler assessment.
LRS  In cases where middle cerebral artery Doppler is not available, twice weekly CTG/NST monitoring 
in cases of late FGR with normal umbilical artery Doppler provides a similar safety net as middle cerebral 
artery Doppler.
⊕⊕○○ Strong
4. Absolute indications for delivery irrespective of gestational age include biophysical profile or CTG/NST 
abnormalities (reduced variability and/or repetitive late decelerations), or severe pre-eclampsia with 
uncontrolled hypertension, HELLP syndrome, or other types of end organ damage.
⊕⊕⊕⊕ Strong
5. In cases of isolated mild SGA (estimated fetal weight at 3rd–9th percentile) with no additional 
abnormalities (i.e. normal fluid and Doppler studies), delivery may be deferred until 37–39 weeks. Until 
then, monitoring should include umbilical artery and middle cerebral artery Doppler at an interval of 
1–2 weeks. For mild SGA at term (≥37 weeks), monitoring with CTG/NST and/or biophysical profile 
1–2 times per week may be considered in addition to Doppler studies.
⊕⊕⊕○ Strong
6. In cases of isolated severe SGA (estimated fetal weight <3rd percentile) with no additional abnormalities, 
delivery may be deferred until 36–38 weeks. Until then, monitoring should include umbilical artery and 
middle cerebral artery Doppler 1–2 times per week. For severe SGA at term (≥37 weeks) monitoring 
with CTG/NST and/or biophysical profile 1–2 times per week may be considered in addition to Doppler 
studies.
⊕⊕⊕○ Strong
7. In cases of FGR with early Doppler changes or mild associated abnormalities (oligohydramnios, suboptimal 
interval growth, pre-eclampsia), delivery may be deferred until 34–37 weeks. Until then, monitoring 
should include CTG/NST and/or biophysical profile twice per week and Doppler 1–2 times per week.
⊕⊕○○ Strong
8. In cases of FGR with umbilical artery absent end-diastolic velocity (AEDV), delivery may be deferred until 
32 weeks. Until then, inpatient monitoring is recommended with CTG/NST and/or biophysical profile 
1–2 times per day and Doppler 3 times per week.
⊕⊕○○ Strong
9. In cases of FGR with umbilical artery reversed end-diastolic velocity (REDV), delivery may be deferred 
until 30 weeks. Until then, inpatient monitoring is recommended with CTG/NST and/or biophysical 
profile twice per day and daily Doppler.
⊕⊕○○ Strong
10. In cases of FGR with abnormal ductus venosus Doppler, delivery may be recommended as early as 
26–30 weeks. Timing should be individualized based on local neonatal outcomes. Intensive inpatient 
monitoring is recommended with CTG/NST and/or biophysical profile twice per day and daily Doppler. Before 
26 weeks, careful and shared decision making with the parents and neonatology team is recommended.
⊕⊕○○ Weak
11. FGR alone is not an indication for cesarean section. Primary cesarean section may be considered in cases 
of early-onset FGR with umbilical artery AEDV/REDV or ductus venosus Doppler changes, abnormal 
CTG/NST or biophysical profile, maternal indications such as severe pre-eclampsia, or contraindications 
for vaginal birth. In the absence of these conditions, induction of labor should be preferred.
⊕○○○ Strong
12. Delivery of FGR fetuses should ideally take place at centers with the appropriate level of neonatal care 
for the gestational age and with the ability to perform urgent cesarean section if needed. During labor, 
continuous fetal heart rate monitoring is recommended.
⊕⊕⊕⊕ Strong
13. The placenta should be sent for histopathological examination where available as it may provide useful 
information for counselling regarding future pregnancies.
⊕⊕○○ Strong
14. The administration of antenatal corticosteroids in FGR pregnancies should follow the same protocol 
used in pregnancies not affected by FGR. Close fetal monitoring should be considered when antenatal 
corticosteroids are administered in fetuses with severe FGR with late Doppler changes.
⊕⊕⊕○ Strong
15. The administration of magnesium sulfate for neuroprotection in preterm FGR pregnancies should follow 
the same protocol used in pregnancies not affected by FGR.
⊕⊕○○ Strong
16. There are currently no proven treatments for FGR. ⊕⊕⊕○ Strong
 Cont.
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1. Growth restricted infants are at an increased risk of short- and long-term morbidity and should be 
followed postnatally more closely than normally grown infants.
⊕⊕○○ Strong
2. Women with a history of placenta-mediated pregnancy complications including FGR are at an increased 
risk of future cardiovascular morbidity and should be advised regarding preventive strategies as 
reviewed in detail in the FIGO postpregnancy initiative on long-term maternal implications of pregnancy 
complications and follow-up considerations.4
⊕⊕⊕○ Strong
3. Women with a history of FGR should be counselled regarding the risk of recurrence based on timing of 
onset, severity of FGR, and placental histopathological findings.
⊕⊕○○ Strong
4. Women with a history of FGR should not be routinely screened for antiphospholipid antibodies in the 
absence of a history of thromboembolism or pregnancy loss.
⊕⊕⊕○ Strong
5. There is no role for screening for hereditary thrombophilias in women with a history of FGR. ⊕⊕⊕○ Strong
6. The following preventive interventions are recommended in women with a history of placenta-mediated 
FGR and those at risk of pre-eclampsia: smoking cessation, aspirin at a dose of 100–150 mg taken in the 
evening starting at 12–16 weeks.
⊕⊕○○ Strong
7. Low-molecular-weight heparin is not recommended for the prevention of FGR in women with a history of 
placenta-mediated FGR.
⊕⊕⊕○ Strong
8. In women with antiphospholipid syndrome and a history of placenta-mediated FGR, low-molecular-
weight heparin may be considered in selected cases, such as in women who have experienced recurrent 
complications despite aspirin treatment (aspirin failure).
⊕⊕○○ Weak
9. Women with a history of FGR should undergo close surveillance of fetal growth starting at 24–28 weeks. ⊕⊕⊕○ Strong
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2  |  TARGET AUDIENCE
This article is directed at multiple stakeholders with the intention 
of bringing attention to the assessment of fetal growth, with a par-
ticular focus on the screening, diagnosis, and management of FGR, 
which is a leading cause of stillbirth and neonatal mortality and mor-
bidity. This article proposes to standardize and provide guidance for 
the screening, prevention, diagnosis, and management of FGR.
The intended target audience includes:
Healthcare providers: all those qualified to care for pregnant 
women (obstetricians, maternal-fetal medicine specialists, general 
practitioners, midwives, nurses, advance practice clinicians, radiol-
ogists, sonographers, pediatricians, and neonatologists).
Healthcare delivery organizations and providers: governments, 
federal and state legislators, healthcare management organizations, 
health insurance organizations, international development agencies, 
and nongovernmental organizations.
Professional organizations: international, regional, and national 
professional organizations of obstetricians and gynecologists, 
obstetric ultrasound, family practitioners, pediatricians, neonatolo-
gists, and worldwide national organizations dedicated to the care of 
pregnant women and their offspring.
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3  |  A SSESSMENT OF QUALIT Y OF 
E VIDENCE AND GR ADING OF STRENGTH 
OF RECOMMENDATIONS
In assessing the quality of evidence and grading of strength of rec-
ommendations, the article follows the terminology proposed by 
the Grading of Recommendations, Assessment, Development and 
Evaluation (GRADE) Working Group.5 This system uses consistent 
language and graphical descriptions for the strength and quality of 
the recommendations and the evidence on which they are based.
Recommendations are classified as strong or conditional (weak) 
(Table S1).6 The strength of recommendation is dependent not only 
on the quality of evidence, but also on factors such as risk–bene-
fit, cost, resource allocation, values, and preferences. Thus, some 
recommendations may be based on low-quality evidence but still 
represent a benefit that outweighs the risks and burdens, and there-
fore may be strongly recommended.
The overall quality of evidence was assessed for each of the rec-
ommendations and expressed using four levels of quality: very low, 
low, moderate, and high (Table S2).7 Considerations for quality of 
evidence include primarily the study design and methodology. As 
such, evidence based on randomized controlled trials is considered 
high-quality evidence, observational studies provide moderate or 
low quality of evidence, and all others are very low. However, other 
parameters must be considered while assessing the level of evidence: 
risk of bias, study limitations, consistency of results, precision, pub-
lication bias, indirectness of evidence, and scarcity of evidence. For 
the quality of evidence, cross-filled circles are used: ⊕○○○ denotes 
very low-quality evidence; ⊕⊕○○ low quality; ⊕⊕⊕○ moderate 
quality; and ⊕⊕⊕⊕ high-quality evidence.
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4  |  FETAL GROW TH RESTRIC TION: 
BACKGROUND, DEFINITION, ETIOLOGY, 
AND RISKS
4.1  |  Background
FGR is a common pregnancy complication that worldwide is a lead-
ing cause of stillbirth, neonatal mortality, and short- and long-term 
neonatal morbidity.8-15 The definition, diagnosis, and optimal man-
agement of FGR have generated controversy as clinicians strive for 
more harmonized care.
The purpose of this article is to provide a summary of the avail-
able evidence and provide recommendations regarding the early 
prediction and prevention, diagnosis, investigation, monitoring, 
and timing of delivery of pregnancies complicated by FGR, with 
the overall goal to decrease the risk of stillbirth and neonatal mor-
tality and morbidity associated with this pregnancy complication. 
Given the variation in resources and expertise available for the 
assessment and monitoring of pregnancies complicated by FGR 
in different countries or regions, we have included, in addition to 
the standard of care or “best” recommendations, specific recom-
mendations for low-resource settings, which are marked as LRS  
in the recommendation tables. Management algorithms for women 
in high-resource and low-resource settings are summarized in 
Figure 1a and 1b, respectively.
4.2  |  Terminology and definitions
FGR is defined as the failure of the fetus to meet its growth potential 
due to a pathological factor, most commonly placental dysfunction. 
Clinically, this is reflected by a drop in fetal size percentiles over the 
course of gestation. However, fetal growth potential is difficult to 
determine, and serial assessments of fetal size to detect a drop in 
fetal weight percentile are usually not available. Instead, care provid-
ers most commonly have only a “snapshot” of fetal weight estima-
tion at a given point in time. Therefore, in clinical practice, small for 
gestational age (SGA), defined as estimated fetal weight (EFW) or 
abdominal circumference below a certain threshold such as the 10th 
or 3rd percentile, is most commonly used to suspect FGR.
The use of SGA as a proxy for FGR has several limitations that 
need to be recognized. First, most SGA fetuses are constitution-
ally healthy small fetuses, whose smallness is merely the result of 
their predetermined growth potential (i.e. false-positive diagnosis of 
FGR). Second, some growth-restricted fetuses, depending on their 
original growth potential and timing of insult, may remain above the 
percentile threshold described above and may thus not be SGA (i.e. 
false-negative diagnosis of FGR). Third, the use of SGA as a proxy 
for FGR is limited by the accuracy of sonographic fetal weight esti-
mation, which has an estimation error of up to ±15%–20%. Finally, 
the diagnosis of SGA is highly dependent on the growth chart being 
used, which can therefore have a considerable effect on the propor-
tion of fetuses or infants flagged as SGA in a given population.
It should be noted that there is inconsistency in the literature 
regarding the terminology described above, where some use the 
term FGR to describe a fetus with an estimated weight below the 
10th percentile for gestational age and the term SGA to describe 
an infant with birth weight below the 10th percentile for gesta-
tional age. However, for the purpose of this article, the term SGA 
is used to indicate an EFW or birth weight below the 10th per-
centile for gestational age, and the term FGR to refer to a small 
fetus that has failed to achieve its growth potential because of a 
pathologic process.
4.2.1  |  Consensus-based definition of placenta-
related FGR
The major member societies of FIGO follow a definition using the 
10th percentile as a means of diagnosing an SGA fetus, which then 
leads to further testing, assessment, and follow-up. There are pro-
posals to address the limitations of this definition, but their validity 
regarding reduction in adverse outcomes needs to be tested. For 
example, in an attempt to overcome some of the limitations de-
scribed above, a consensus-based definition for placenta- mediated 
FGR has been proposed via a Delphi procedure.1 To decrease the 
likelihood of false-positive and false-negative diagnosis of FGR, 
the consensus definition was based on a combination of measures 
of fetal size (fetal weight estimation and abdominal circumference) 
and abnormal Doppler findings in the umbilical, uterine, and mid-
dle cerebral arteries, as described in Box 1. The implementation of 
this definition is limited by the lack of a recommendation on which 
growth chart should be used to define the 10th and 3rd percentiles 
for EFW and fetal abdominal circumference. In addition, further 
research is needed to correlate this definition with adverse peri-
natal outcomes.
4.2.2  |  Early- versus late-onset FGR
It has been suggested that FGR should be broadly classified, based 
on gestational age at the time of diagnosis, into early-onset FGR 
(<32 weeks) and late-onset FGR (≥32 weeks). The rationale under-
lying this classification is based on differences between these two 
phenotypes of FGR in severity, natural history, Doppler findings, 
association with hypertensive complications, placental findings, and 
management.16-18
Early-onset FGR has a prevalence of 0.5%–1%, is usually more 
severe, and is more likely to be associated with abnormal umbili-
cal artery Doppler than late-onset FGR. The underlying placental 
pathology is frequently similar to that observed in cases of early- onset 
pre-eclampsia (maternal vascular malperfusion), which explains the 
strong association of early-onset FGR with pre-eclampsia. Therefore, 
early-onset FGR is usually easier to detect, and the natural history 
tends to follow a predictable sequence of Doppler changes in the 
umbilical artery and ductus venosus. The main challenge in cases of 
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early-onset FGR is management (i.e. timing of delivery), by attempt-
ing to determine the optimal balance between the opposing risks of 
stillbirth and prematurity.19
Late-onset FGR is more common than early-onset FGR with 
a prevalence of 5%–10%. In contrast to early-onset FGR, it is 
usually milder, is less likely to be associated with pre-eclampsia, 
and is usually associated with normal umbilical artery Doppler. 
Therefore, the main challenge with regard to late-onset FGR is di-
agnosis, while management (i.e. delivery) is relatively simple given 
that the diagnosis is commonly made during the late-preterm or 
term periods, where the risks associated with delivery are rela-
tively small. The diagnosis of late-onset FGR mainly relies on 
adaptive changes in the cerebral circulation (“redistribution” or 
“brain-sparing effect”), which is reflected by low resistance to 
flow in the middle cerebral artery thereby generating a low cere-
broplacental ratio, as described in section 8.1.7. Given that the 
umbilical artery and ductus venosus Doppler studies are usually 
normal in cases of late-onset FGR, the natural history in these 
F I G U R E  1 A  Approach to screening, diagnosis, and management of fetal growth restriction in high-resource settings. Abbreviations: FGR, 
fetal growth restriction; NST, nonstress test; PCR, polymerase chain reaction; SFH, symphysis–fundal height.
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F I G U R E  1 B  Approach to screening, diagnosis, and management of fetal growth restriction in low-resource settings. Abbreviations: FGR, 
fetal growth restriction; NST, nonstress test; PCR, polymerase chain reaction; SFH, symphysis–fundal height.
Box 1 Consensus-based definitions for fetal growth restriction.
Early-onset FGR (<32 weeks)
• EFW or AC <3rd percentile
 or
• UA with AREDV
 or
• EFW or AC <10th percentile, combined with one or more of the 
following:
a. UA PI >95th percentile
b. UtA PI >95th percentile
Late-onset FGR (≥32 weeks)
• EFW or AC <3rd percentile
 or
• ≥2 of the following 3 criteria:
a. EFW or AC <10th percentile
b. EFW or AC crossing percentiles >2 quartiles on growth 
percentiles
c. CPR <5th percentile or UA PI >95th percentile
Abbreviations: AC, fetal abdominal circumference; AREDV, absent or reversed end-diastolic velocity; CPR, cerebroplacental ratio; 
EFW, estimated fetal weight; PI, pulsatility index; UA, umbilical artery; UtA, uterine artery. Adapted from Gordijn et al.1
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cases is less predictable and there is a risk of sudden decompen-
sation and stillbirth.16,19
4.3  |  Etiology of fetal growth restriction
FGR is often the result of one or more maternal, placental, or fetal 
disorders that interfere with the normal mechanisms regulating fetal 
growth.20,21 The most common etiologies of FGR are listed in Box 2. It is 
important to note that there is often confusion in the literature between 
“etiologies” (or pathogenetic pathways) and “risk factors” for FGR. For 
example, although maternal conditions such as chronic hypertension, 
kidney disease, systemic lupus erythematosus, and long-standing dia-
betes are often listed as “maternal etiologies” for FGR, these conditions 
should probably be viewed instead as maternal risk factors for abnormal 
placentation that may result in placenta-mediated FGR.
Given that maternal nutrition and fetal growth are closely 
related,22,23 maternal undernutrition is an important cause of FGR 
worldwide.24-26 The impact of maternal undernutrition on fetal growth 
depends on its timing and severity.20 To date, maternal interventions 
in dietary advice and modifications have lacked significant success in 
preventing FGR. While the mechanisms by which maternal anemia 
contributes to FGR are unclear, both impaired nutrient transport to 
the fetus 27 and abnormal placental adaptation to low maternal hemo-
globin 28 have been suggested as potential mechanisms.
Abnormal placentation is a common cause of FGR, 29 which is 
often diagnosed by ultrasound Doppler studies 30 and typical histo-
pathological placental findings.31-33
Chromosomal abnormalities have been suggested to contrib-
ute to up to 5% of FGR cases; triploidy and trisomy 13 and 18 are 
important considerations in early-onset FGR and the risk of many 
aneuploidies is higher in the presence of structural fetal anom-
alies.34-36 In 1%–6% of cases of FGR with normal karyotype, sub-
microscopic (micro) duplications/deletions can be found using 
chromosomal microarray analysis,35 even when FGR is an apparently 
isolated finding.37 FGR is also more prevalent in fetuses with struc-
tural malformations, and the risk increases when multiple anomalies 
are present.38
FGR is related to intrauterine infection in up to 5% of cases.20,39 
Viral agents such as rubella, cytomegalovirus, HIV, and Zika are 
common causes of infection-related FGR.40-44 Protozoan infec-
tions like toxoplasmosis and malaria are another important cause, 
especially in endemic areas.45,46 The main mechanism involved in 
the pathogenesis of FGR in these cases is a decline in cell popu-
lation.20 Finally, maternal exposure to teratogens such as radia-
tion,47 illicit drugs,48,49 and alcohol50 is another important etiology 
of FGR.
4.4  |  Risks associated with fetal growth restriction
The main short- and long-term risks associated with FGR are listed 
in Box 3. It is associated with both fetal and obstetric complica-
tions. The most devastating complication is stillbirth,51-53 and there 
is a well-established inverse relationship between weight percentile 
and the risk of stillbirth,54-57 which is more pronounced in the early 
Box 2 Common etiologies of fetal growth 
restriction.
Suboptimal uteroplacental perfusion of fetal nutrition
a. Maternal (preplacental) factors
• Hypoxemia (chronic lung disease, high altitude)
• Anemia
• Smoking, substance abuse (cocaine, 
methamphetamines)
• Malabsorption, poor weight gain
• Environmental toxins: air pollution, heavy metals 
(lead, mercury), perfluorooctanoic acid (PFOA)
b. Placental factors
• Maternal vascular malperfusion pathology (infarction, 
fibrin deposition, chronic abruption)
• Fetal vascular malperfusion pathology
• Chronic placental inflammation (e.g. villitis of 
unknown etiology)
• Confined placental mosaicism
c. Umbilical cord (postplacental) factors
• Increased coiling
• Increased cord length
• True cord knot
• Single umbilical artery
• Marginal or velamentous cord insertion
Fetal disorders
• Genetic disorders (chromosomal, microdeletions/
duplications, single site mutations, epigenetic 
disorders)
• Structural anomalies (e.g. congenital heart disease, 
gastroschisis)
• Congenital infections (cytomegalovirus, 
toxoplasmosis, herpes, rubella, syphilis, Zika virus, 
malaria)
• Teratogen exposure (drugs, toxins)









• Neonatal morbidity (hypoglycemia, hyperbilirubinemia, 




• Metabolic syndrome (obesity, hypertension, diabetes, 
cardiovascular disease)
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preterm period than at term.58 FGR is an important cause of iatro-
genic preterm birth,59 as early delivery remains the main and per-
haps only strategy for the prevention of stillbirth in cases of severe 
FGR.16,60 FGR is also an independent risk factor for spontaneous 
preterm birth.61 Other obstetric complications associated with FGR 
include pre-eclampsia and placental abruption, as the pathophysiol-
ogy of these conditions is often closely related.29,30,62-66
Despite ongoing improvements in neonatal care, FGR is associ-
ated with increased neonatal mortality and short-term morbidity. 
The risk of perinatal mortality in term FGR is reported to be five- 
to 10-fold higher than in appropriately grown neonates.57,61,67 The 
severity of FGR, Doppler abnormalities, and associated prematurity 
are independent predictors of neonatal complications.68 Among 
preterm infants, the co-presence of FGR further increases the risk 
of certain prematurity-related complications such as respiratory 
morbidity, intraventricular hemorrhage, necrotizing enterocolitis, 
and metabolic disorders.57 Among term infants, FGR increases 
the risks of low cord artery pH,69 low Apgar score,69 and neo-
natal complications such as hypoglycemia, hypothermia, and 
jaundice.70-72
Growth-restricted infants are also at risk of long-term compli-
cations including neurodevelopmental impairment 11,73-78 and non-
communicable diseases.15,79-82 This is discussed in greater detail in 
section 9.1 (Infant follow-up).
4.5  |  Recommendations






1. Small for gestational age (SGA) is defined as an estimated fetal weight or birth weight below the 10th 
percentile for gestational age.
⊕⊕⊕⊕ Strong
2. The definition of FGR should be based on a combination of measures of fetal size percentile and Doppler 
abnormalities. We support the consensus-based definitions for early and late fetal growth restriction by 
Gordijn et al.1 as described in Box 1 (section 4.2.1).
LRS  In low-resource settings, FGR may be defined in the same way as SGA (fetal weight or birth weight 
below the 10th percentile for gestational age).
⊕⊕○○ Strong
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5  |  E ARLY PREDIC TION AND 
PRE VENTION OF FETAL GROW TH 
RESTRIC TION
Early prediction of FGR is important as it can identify women at 
high risk of FGR who may benefit from preventive interventions and 
close monitoring during pregnancy. Box 4 lists the most common risk 
factors for FGR. While the predictive value of individual risk factors 
is low, clinical prediction models that are based on combinations of 
the risk factors outlined below can considerably improve the predic-
tion of FGR. One important limitation of most of the studies on early 
prediction of FGR is the lack of a gold standard for the antenatal or 
postnatal diagnosis of FGR. As such, there is wide variation among 
studies regarding the outcomes being predicted, including either 
SGA (birth weight below the 10th or 3rd percentile) or adverse peri-
natal outcomes that are associated with (but are not specific to) FGR. 
As many SGA infants are constitutionally small and healthy, differ-
entiating between healthy small fetuses and those that are small due 
to FGR is critically important. As a rule, the prediction of early-onset 
severe FGR is better than of late-onset FGR.
5.1  |  History-based risk factors
Several maternal factors influence fetal growth and the risk of FGR: 
advanced maternal age, racial/ethnic origin (e.g. South Asian), con-
sanguinity, low body mass index, nulliparity, use of recreational 
drugs and alcohol, assisted reproductive technology, and medi-
cal disorders such as chronic hypertension, diabetes mellitus, and 
autoimmune conditions (Box 4).83-89 Cigarette smoking is a com-
mon risk factor for FGR and reduces birth weight by an average of 
200 g in a dose–response manner.90 In a cohort of 33 602 pregnan-
cies, maternal characteristics predicted 37% of women who subse-
quently delivered SGA neonates (birth weight <5th percentile) at a 
false-positive rate of 10%.83
Some risk factors for FGR are especially relevant in low- resource 
countries. In a recent review from Africa, the main risk factors 
reported were low maternal nutritional status, HIV infection, 
malaria, and hypertensive diseases. Based on these findings, the 
authors concluded that to a large extent FGR in Africa is preventable 
through established interventions for malaria, HIV, and maternal 
undernutrition.42 In addition, exposure during pregnancy and lacta-
tion to toxic environmental chemicals and heavy metals has become 
a growing problem, especially in low-resource countries.91
5.2  |  Biochemical markers
At this point there is no role for routine screening with serum biomark-
ers for FGR. However, when biochemical markers are available as part 
of prenatal genetic screening for trisomy 21, it may be reasonable to 
use this information for the purpose of risk stratification for FGR.
The placenta releases multiple factors into maternal circulation 
from the early stages of pregnancy, and first-trimester serum levels 
of some of these factors have been shown to be associated with 
subsequent placenta-mediated complications.92,93 Low levels of 
pregnancy-associated plasma protein-A (PAPP-A), a placental gly-
coprotein produced by the syncytiotrophoblast layer, have been 
associated with adverse pregnancy outcomes including SGA. A 
meta-analysis including 32 studies and 175 240 pregnancies found 
that PAPP-A levels below the 5th percentile had a moderate asso-
ciation with birth weight below the 10th percentile (OR 2.08, pos-
itive predictive value of 18%), while the association was stronger 
for PAPP-A levels below the 1st percentile (OR 3.4; positive predic-
tive value of 28%).94 Thus, although women with low PAPP-A are 
at increased risk for FGR, the majority of these women will have 
a normal pregnancy outcome, especially as an isolated biomarker 
in healthy women. However, a low PAPP-A level is often consid-
ered an indication for closer monitoring of fetal growth.95 Elevated 
second-trimester maternal serum levels of alpha-fetoprotein are 
thought to reflect abnormal placental permeability and are associ-
ated with increased risk of placenta- mediated complications includ-
ing FGR and stillbirth.96,97 The combination of low PAPP-A in the 
first trimester and high alpha- fetoprotein in the second trimester is 
particularly predictive of severe FGR.98 Elevated human chorionic 





• Living in high altitude
• Severe anemia, hemoglobinopathies




• Chronic kidney disease
• Systemic lupus erythematosus
• Inflammatory bowel disease
• Antiphospholipid syndrome
• Pregestational diabetes (long standing)
c. Obstetric history






• Uterine artery: pulsatility index >95th percentile
• Uterine artery: bilateral notching
• Marginal or velamentous cord insertion
• Two-vessel cord (single umbilical artery)
• Abnormal placental morphologya
• Decreased fetal growth velocity
Abbreviations: FGR, fetal growth restriction; PlGF, placen-
tal growth factor; PAPP-A, pregnancy-associated plasma 
protein-A; AFP, alpha-fetoprotein.
aRefers to placental dimension (short-based thick placenta) 
and texture (calcifications, echogenic cystic lesions).
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gonadotropin (hCG) levels greater than 2.5 MoM in the second tri-
mester, alone or combined with high alpha-fetoprotein levels, are 
also associated with an increased risk of SGA.99
Angiogenic factors play a key role in the regulation of placental 
vascular development.100 Placental growth factor (PlGF) is a pro-
angiogenic factor highly expressed in the syncytiotrophoblast and 
the maternal endothelium. Impaired placentation is associated with 
reduced placental production of this protein. Low first-trimester 
PlGF levels have been shown to be associated with adverse preg-
nancy outcome including pre-eclampsia and SGA.101-104 In a case–
control study of 296 pregnancies with SGA and 609 controls, the 
detection rate of low PlGF for SGA at a false-positive rate of 5% 
and 10% was 15% and 21%, respectively. The combined use of PlGF 
and PAPP-A increased the detection rate to 19% and 27%, respec-
tively.103 A multicenter screening study found that the detection 
rate of a combined screening by maternal factors, fetal biometry, 
and serum PlGF and alpha-fetoprotein at 19–24 weeks for the deliv-
ery of SGA infants below the 5th percentile at less than 32, 32–36, 
and greater than or equal to 37 weeks of gestation was 100%, 76%, 
and 38%, respectively, at a false-positive rate of 10%.96
Findings are less consistent for soluble fms-like tyrosine kinase-1 
(sFlt-1), an antiangiogenic factor released from the placenta that results 
in maternal endothelial dysfunction characteristic of pre-eclampsia.105 
Although maternal serum sFlt-1 levels are known to be elevated in 
pre-eclamptic pregnancies, a large case–control study demonstrated 
that high levels of sFlt-1 at 10–14 weeks were actually associated 
with a slightly reduced risk of SGA (OR 0.92; 95% CI, 0.88–0.96).101 
Therefore, the sFlt-1:PlGF ratio test used to diagnose pre-eclampsia 
should not be used in the first trimester as a screening test for FGR.106
5.3  |  Ultrasound markers
Several ultrasound-based markers have been shown to be predictive 
of FGR, including uterine artery Doppler, placental morphology, and 
placental volumes. However, given their modest predictive accuracy, 
they cannot be recommended for universal screening for FGR.
Increased uterine artery resistance largely reflects a failure of 
extravillous cytotrophoblast invasion and transformation of the spi-
ral arteries and is associated with the development of pre-eclampsia 
and FGR due to maternal vascular malperfusion of the placenta.107
First- and second-trimester abnormal uterine artery Doppler 
waveforms, defined as mean pulsatility index above the 95th per-
centile, have been shown to be associated with FGR.108-110 In a large 
prospective cohort study of 4610 nulliparous women, uterine artery 
pulsatility index at 11+0 to 13+6 weeks predicted 60% of preterm and 
17% of term SGA infants at a false-positive rate of 10%.111 Although 
uterine artery Doppler shows promise, especially for the predic-
tion of early-onset FGR, current evidence does not support routine 
screening with uterine artery Doppler for FGR in low- or high-risk 
pregnancies.112
Sonographic evaluation of the placenta is a routine part of 
the obstetric ultrasound examination. A method for systematic 
two-dimensional (2D) placental ultrasound examination has been 
described, often in combination with other parameters 30,113,114 
Abnormal placental morphology is defined by placental dimensions, 
shape, texture, and cord insertion. Placental shape is considered 
abnormal when the placental thickness is above 4 cm or greater than 
50% of placental length. Placental texture is defined as normal when 
it is homogenous, and abnormal when the placenta is heterogeneous 
and contains multiple echogenic cystic lesions or has a jelly-like 
appearance with turbulent uteroplacental flow.115,116 Placental cord 
insertion is defined as central (>2 cm from placental disc margin), 
marginal (within 2 cm of margin), or velamentous (inserting into the 
surrounding membranes).114 In a cohort of 60 high-risk women with 
abnormal uterine artery Doppler, women with abnormal placental 
shape at 19–23 weeks had higher odds of FGR (OR 4.7) than women 
with normal placental shape.108 However, the use of 2D placental 
imaging has significant limitations, including difficulty in assessing 
nonanterior placentas and a wide variability in the morphology of 
normal placentas. Furthermore, there are no large-scale prospective 
studies validating the use of this modality for prediction of FGR.114
Improvements in ultrasonographic imaging provide a tool for 
estimating placental volume using three- and four-dimensional scan-
ning techniques. Placental volume has been proposed as a marker 
for various obstetric complications related to defective placental 
function, including FGR.117,118 A systematic review estimating the 
value of first-trimester 3D placental volume for the prediction of 
SGA found a detection rate of 24.7% at a 10% false-positive rate.119 
Another parameter is the placental quotient, defined as the ratio of 
the placental volume to the fetal crown–rump length. The placen-
tal quotient was reported to have a high negative predictive value 
for perinatal complications but was not very useful when used 
for screening of SGA in a low-risk population, with a sensitivity of 
27.1%.120 The discriminatory ability of placental volume alone for 
SGA appears to be modest, but may be integrated into a multivari-
able screening model. However, the use of 3D placental volume as 
a routine screening tool for FGR is limited by the need for proper 
equipment and training required to obtain these measurements in a 
reproducible manner.
5.4  |  Prediction models
Currently there is no single screening test sufficiently predictive of 
FGR to recommend routine clinical use. Investigations are underway 
to combine various tests, but such prediction models have not been 
sufficiently validated in terms of outcomes studies and therefore 
must be considered investigative protocols at this time. In a pro-
spective cohort of 4970 women, the combination of first-trimester 
maternal serum PAPP-A, beta hCG, maternal blood pressure, and 
uterine artery Doppler performed in the first trimester had a detec-
tion rate of 73% for early SGA (<34 weeks) but only 32% for late SGA 
(≥34 weeks).19 A different model that included maternal character-
istics, first-trimester blood pressure, uterine artery pulsatility index, 
PlGF, and sFlt-1 was evaluated in a larger cohort of 9150 women 
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and achieved a detection rate of 86% for early-onset FGR and 66% 
for late-onset FGR, both at a false-positive rate of 10%.19,121 In the 
second trimester, the SCOPE consortium examined 5606 healthy 
nulliparous women with singleton pregnancies and found that the 
combination of clinical risk factors, 15-week biomarkers (53 biomark-
ers were used), and 20-week ultrasound (fetal biometry and Doppler 
studies of the umbilical and uterine arteries) had only a moderate 
detection rate for SGA below the 10th percentile, with a positive 
predictive value of 32% and a negative predictive value of 91%.122
5.5  |  Prevention of fetal growth restriction in high-
risk populations
5.5.1  |  Lifestyle modifications
Ideally, all women should plan their pregnancies, adopting a healthy 
lifestyle and optimizing any medical conditions and their body mass 
index. The preconception period provides an opportunity for health 
promotion with the aim of reducing accepted risk factors, including 
those associated with FGR.123
Insufficient gestational weight gain has been associated with an 
increased risk of FGR, especially in women with low body mass index 
(BMI, calculated as weight in kilograms divided by height in meters 
squared).124 Recognizing that these associations are only based on 
observational data, we still believe that it would be reasonable to 
recommend monitoring of weight gain and informing women of the 
target weight gain range, as recommended by the 2009 Institute of 
Medicine guidelines.125 These guidelines recommend a total gesta-
tional weight gain of 12.5–18 kg (28–40 lb) for underweight women 
(BMI <18.5); 11.5–16 kg (25–35 lb) for the normal weight group (BMI 
18.5–24.9); 7–11.5 kg (15–25 lb) for overweight women (BMI 25.0–
29.9); and 5–9 kg (11–20 lb) for obese women (BMI ≥30).126
Substance use, including smoking, alcohol, and illicit drugs, is 
associated with low birth weight and increased perinatal morbidity 
and mortality.90 Interventions to promote smoking cessation during 
pregnancy have been shown to result in a reduction in low birth 
weight (RR 0.81) and an increase in mean birth weight (+33 g).127 
Women should be advised that smoking cessation at any point in 
gestation is of benefit, and that the greatest benefit is associated 
with cessation before 15 weeks of pregnancy.128 The risk of SGA 
with alcohol intake is increased with as little as one drink per day.129
5.5.2  |  Medical interventions
Most studies on early prevention of placental complications have 
focused on pre-eclampsia, with the results often being extrapolated 
to FGR due to the common pathophysiology. However, to date, 
other than lifestyle modifications, no medical interventions to pre-
vent FGR have been clearly established.
Aspirin is recommended for women at increased risk of 
pre-eclampsia, but there is some evidence that it may also reduce 
the risk of FGR 130,131 In a recent meta-analysis of 45 trials that 
included 20 909 women at high risk of pre-eclampsia, the admin-
istration of aspirin starting at less than or equal to 16 weeks of 
pregnancy reduced the risk of FGR by nearly half (RR 0.56; 95% CI, 
0.44–0.70), with higher dosages of aspirin associated with a greater 
reduction, favoring a dose of 100–150 mg.132 A second individual 
patient data meta-analysis also supported earlier initiation of aspirin 
for the prevention of FGR, with an RR of 0.76 (95% CI, 0.61–0.94) for 
women randomized before 16 weeks versus an RR of 0.95 (95% CI, 
0.84–1.08) for women randomized at 16 weeks or beyond.131 One 
randomized trial found that evening but not morning administration 
of aspirin is associated with reduction in the rate of pre-eclampsia 
and FGR.133 However, it should be emphasized that most of the 
available data on aspirin come from studies that focused on the pre-
vention of pre-eclampsia as the primary outcome in women at high 
risk of pre-eclampsia, with the prevention of FGR considered only as 
a secondary outcome. Furthermore, in the largest trial to date on the 
use of aspirin for the prevention of pre-eclampsia (ASPRE trial), aspi-
rin was not associated with a reduction in the risk of SGA below the 
10th, 5th, or 3rd percentile.130 However, we believe that given the 
safety of aspirin and the overlap in the risk factors and pathogenesis 
of pre-eclampsia and FGR, it is reasonable to recommend aspirin to 
women at high risk of FGR, using the same regimen of aspirin used 
for women at high risk of pre-eclampsia. Most international guide-
lines recommend 100–150 mg aspirin to prevent FGR in women at 
high risk.134
The adjunct role of heparin in combination with aspirin to pre-
vent placenta-mediated complications in high-risk situations was 
originally attributed to its anticoagulant properties and the specu-
lative prevention of placental thrombosis. However, in vitro and in 
vivo data suggest heparins may have other biological properties 
including anti-inflammatory, complement inhibition, and proan-
giogenic activities.135-138 A study-level meta-analysis of six trials 
including 848 women showed that low-molecular-weight heparin 
(LMWH) was associated with a reduction in the composite out-
come of pre- eclampsia, birth weight below the 10th percentile, pla-
cental abruption, or pregnancy loss after 20 weeks (RR 0.52; 95% 
CI, 0.32–0.86) with similar risk reduction for SGA below the 10th 
and 5th percentiles. However, the higher-quality trials suggest no 
treatment effect,139 and a subsequent individual patient data me-
ta-analysis looking at the same composite outcome found no ben-
eficial effect of LMWH treatment (RR 0.64; 95% CI, 0.36–1.11).140 
Likewise, the enoxaparin for pre-eclampsia and intrauterine growth 
restriction (EPPI) trial included women at high risk for placenta-me-
diated complications (with a high proportion of women with prior 
FGR) and showed no difference in the rate of the composite out-
come (pre-eclampsia or SGA <5th percentile) between treated and 
nontreated women.141 Therefore, based on the most up-to-date ev-
idence, LMWH cannot be recommended for the prevention of FGR 
in women at high risk of placenta-mediated complications. Its use 
for the prevention of FGR should therefore be limited to research 
settings, for example in women already on aspirin who are found to 
have abnormal levels of angiogenic markers prior to fetal viability.142
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5.6  |  Recommendations






1. Women should undergo risk stratification for FGR (and other placenta-mediated complications) at the 
time of the first-trimester antenatal visit using history-based (medical and obstetric) risk factors.
⊕⊕⊕○ Strong
2. There is no evidence to support the routine use of biochemical markers for the prediction of FGR. 
However, when such information is available as part of prenatal genetic screening for trisomy 21, it may 
be reasonable to use this information for the purpose of risk stratification for FGR (and other placenta-
mediated complications).
⊕⊕⊕○ Strong
3. Ultrasound-based markers and multiparameter algorithms have only a moderate predictive accuracy for 
FGR, and therefore currently cannot be recommended for universal screening.
⊕⊕⊕○ Strong
4. Women at high risk for FGR should undergo close surveillance of fetal growth starting at 24–28 weeks.
LRS  In low-resource settings, the frequency and type of monitoring may be limited by the availability 
of obstetric ultrasound.
⊕⊕⊕○ Strong
5. Women should be advised that smoking cessation and elimination of alcohol and illicit drugs can 
decrease the risk of FGR.
⊕⊕⊕○ Strong
6. Women should be advised on the association of insufficient gestational weight gain with FGR and be 
informed regarding their target weight gain range.
⊕⊕⊕○ Strong
7. There are insufficient data to recommend routine treatment with aspirin in all women at high risk of FGR. 
Treatment with aspirin at a dose of 100–150 mg starting at 12–16 weeks may be considered in selected 
cases such as women who are at high risk of pre-eclampsia or those with a history of placenta-mediated 
FGR.
⊕⊕○○ Weak
8. Low-molecular-weight heparin is not recommended for the prevention of FGR in women at high risk of 
FGR and its use should be limited to research settings.
⊕⊕⊕○ Strong
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6  |  DETEC TION OF FETAL GROW TH 
RESTRIC TION
Detection of FGR is based on the identification of a fetus that is 
smaller than expected for gestational age, through either physical 
examination (symphysis–fundal height, SFH) or ultrasound.
6.1  |  Symphysis–fundal height
Measurement of SFH using a tape is a simple, inexpensive, and 
widely used strategy to screen for FGR.143-146 SFH is measured with 
the woman in a supine position using a nonelastic metric tape after 
she has emptied her bladder. To decrease the interobserver vari-
ability, a standardized technique for measuring SFH should be fol-
lowed.144,145 SFH is defined as the distance from the upper border 
of the symphysis pubis bone to the top of the uterine fundus.145 
SFH measured in centimeters between 24 and 38 weeks of ges-
tation approximates the gestational age.147 Numerous local charts 
are currently used worldwide,148-156 with the recent addition of an 
international standard for SFH based on serial measurements.145 
However, the accuracy of SFH measurement in predicting SGA 
(EFW <10th percentile) is limited, and there are no randomized con-
trolled trials that compare SFH measurement with serial ultrasound 
evaluation of fetal biometry.157 In a meta-analysis of 34 observa-
tional studies, SFH was reported to have a sensitivity of 58% and a 
specificity of 87% for predicting birth weight below the 10th per-
centile. There was marked heterogeneity between studies, mainly 
due to the use of different SFH charts.158 A single SFH meas-
urement at 32–34 weeks of pregnancy has been reported to be 
approximately 65%–85% sensitive and 96% specific for detecting 
FGR.143 It is important to acknowledge that factors such as mater-
nal obesity, uterine leiomyomas, and polyhydramnios may further 
limit the accuracy of SFH as a screening tool.144,159
6.2  |  Sonographic fetal weight estimation
Sonographic fetal biometry is the cornerstone for detection of fetal 
growth disorders. Standard fetal biometry includes assessment of 
head circumference (HC), biparietal diameter, abdominal circumfer-
ence (AC), and femur length (FL). Measurement of these biomet-
ric indices should be obtained by an experienced individual and in 
a standardized manner, as has been previously described.160 Fetal 
weight is estimated based on various combinations of the four bio-
metric indices described above, using one of many published equa-
tions.161-165 The accuracy of most equations falls within the range of 
±10%, and the error has been shown to be greater at the extremes of 
fetal weight, and to be affected by factors such as fetal sex, presen-
tation, and plurality (greater in twin gestations).162-164,166-171 Several 
studies have compared the accuracy of various equations. Most 
studies concluded that equations that are based on 3–4 biometric 
indices (rather than only 1–2 indices) provide the most consistent 
and accurate results. A recent systematic review 165 found that the 
Hadlock equation, based on three indices (HC, AC, and FL: Log10 we
ight = 1.326 − 0.00326*AC*FL + 0.0107*HC + 0.0438*AC + 0.158*F
L), 2 provided the greatest accuracy. Since the accuracy of the various 
equations may vary between different populations, it may be rea-
sonable for radiologists, sonographers, or care providers to choose 
an equation that has been validated within their local population and 
within the gestational age range in which it will be used. However, if 
such information is not available—a very frequent scenario—it seems 
reasonable to use the Hadlock equation as described above.
6.3  |  Is there a role for routine third-trimester 
ultrasound to assess fetal growth?
In many countries, measurement of SFH is the primary screening 
tool for FGR in low-risk pregnancies and ultrasound measurement of 
fetal biometry is performed only when indicated on the basis of risk 
factors or abnormal SFH.134,143,172-174 However, this approach fails 
to identify the majority of FGR infants,146 a concerning finding given 
that undetected FGR is associated with increased risk of adverse 
perinatal outcome and stillbirth.53,175
An alternative approach is to perform a routine third-trimester 
ultrasound for fetal weight estimation. However, a strategy for rou-
tine third-trimester ultrasound in low-risk pregnancies is not sup-
ported by available data and cannot be recommended.176-178
A meta-analysis of 13 trials assessed the effect of routine 
sonographic weight estimation at more than 24 weeks of gestation 
on pregnancy outcomes in both unselected and low-risk pregnan-
cies.178 The authors found no association between routine sono-
graphic EFW and adverse pregnancy outcomes including perinatal 
mortality, preterm birth, induction of labor, or cesarean section. In 
a recent randomized controlled trial of women with uncomplicated 
pregnancies, the use of serial (every 4 weeks) third-trimester ultra-
sound was superior to routine care in the detection of a composite 
outcome of fetal growth or amniotic fluid abnormalities (RR 3.43; 
95% CI, 1.64–7.17).179 However, it is important to note that the inci-
dence of maternal or fetal morbidity was not significantly different 
between the groups. Similar results were reported by others.180 
In contrast, the Pregnancy Outcome Prediction (POP) study pro-
spectively assessed 3977 women and compared the detection 
of SGA (birth weight <10th percentile) by routine ultrasound ver-
sus clinically indicated ultrasound in the third trimester.181 The 
detection rate of SGA was nearly tripled in the routine ultrasound 
group (57% vs 20%). The risk of neonatal morbidity was increased 
only in the subset of SGA fetuses with fetal abdominal circumfer-
ence growth velocity in the lowest decile (RR 3.9; 95% CI, 1.9–8.1), 
emphasizing the importance of combined analysis of fetal biometry 
and fetal growth velocity for better detection of fetuses at risk.182 
Furthermore, it has been suggested that the prediction of FGR based 
on routine third-trimester ultrasound can be improved by integrating 
EFW with additional biomarkers. A combined screening model that 
included maternal characteristics, third-trimester EFW and placental 
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Doppler, and biochemical markers (PlGF and estriol) achieved better 
performance than EFW alone in the detection of FGR (77% vs 64%) 
at a 10% false-positive rate.183
There are many conceptual explanations to support third- 
trimester ultrasound as it can assist in the diagnosis of clinically 
significant  findings other than FGR, including fetal malpresen-
tation,184 disorders of amniotic fluid, and fetal anomalies,185,186 
especially when combined with Doppler measurements and bio-
chemical markers.95,187-189 However, there is no evidence that this 
information improves outcomes when performed routinely in low-
risk pregnancies.
6.4  |  Which growth chart should be used to 
determine fetal weight percentile?
The interpretation of sonographic EFW depends on gestational age 
and is commonly classified as appropriate for gestational age, SGA, 
or large for gestational age, based on the calculation of EFW per-
centile using one of the many available growth charts. The choice 
of growth chart has been shown to have a considerable impact on 
the proportion of fetuses classified as either SGA or large for ges-
tational age.190,191 Over the past several years there has been an 
ongoing debate regarding the optimal growth chart that should be 
used, and numerous studies have compared the performance of 
a wide variety of charts in different populations with conflicting 
results. Prior to further discussion of specific charts, it is important 
to clarify the terminology and the types of charts that are currently 
available.
6.4.1  |  Growth references versus growth standards
Growth references are descriptive charts that provide information 
on the distribution of weight of all newborns in a given population, 
and as such they include both normal and complicated pregnancies. 
Although growth references are useful as they provide informa-
tion on the overall distribution of birth weight in the population, 
their use for the purpose of antenatal detection of FGR may be 
challenging as they are affected by the rate of pathologies in the 
population. For example, in populations with a high rate of large 
fetuses (e.g. due to a high rate of obesity and diabetes), the refer-
ence would be shifted upward. Similarly, in populations with a high 
rate of FGR (e.g. due to a high rate of malnutrition), the reference 
would be shifted downward.
For that reason, it may be reasonable to prefer growth standards 
over growth references for the antenatal detection of FGR. Growth 
standards are prescriptive charts that are based only on low-risk 
or uncomplicated pregnancies, and as such provide information on 
what is the optimal fetal growth. There is variation between different 
growth standards with regard to the definition of “low-risk” pregnan-
cies; while some standards excluded women with pre-existing med-
ical conditions and pregnancy complications, others also excluded 
women below or above certain height or weight, women with subop-
timal nutrition, low socioeconomic status, exposure to air pollution, 
high altitude etc. Since growth standards include only low-risk un-
complicated pregnancies, their distribution is usually narrower (i.e. 
the 10th and 90th percentiles are closer to the mean) compared with 
growth references.
One important and practical aspect regarding the use of refer-
ence versus standard charts relates to the weight percentile thresh-
old that should be used to trigger further evaluation for FGR. When 
using a growth reference, it is reasonable to use the 10th percen-
tile for that purpose, as a considerable proportion of infants below 
the10th percentile will be affected by pathology. In the case of 
growth standard, however, using the same threshold of the 10th per-
centile would, per definition, identify 10% of the low-risk pregnan-
cies as suspected for FGR, which is not practical. Therefore, when 
using a growth standard, a lower threshold—such as the 5th or 3rd 
percentile—should be used to indicate further evaluation for FGR.
6.4.2  |  Charts based on birth weight versus 
sonographic fetal weight estimation
A second important distinction is between growth charts that 
are based on birth weight versus those that are based on sono-
graphic EFW. Birth weight-based charts rely on cross-sectional 
data of infant birth weights across the full range of gestational 
ages, usually obtained from large databases. Different types of 
regression techniques are then used to calculate the mean and 
various percentiles of birth weight across gestation. These charts 
are commonly used as they are easy to develop. However, their 
main limitation is that infants born prematurely (before 37 weeks) 
are more likely to be affected by placental dysfunction and to be 
growth restricted. Therefore, these charts are likely to underes-
timate the optimal weight of fetuses during the preterm period, 
which in turn may lead to an underdiagnosis of FGR before 
37 weeks. This is illustrated in Figure 2, where the birth weight-
based chart of Alexander (USA)192 is compared with several ultra-
sound-based charts.
Therefore, it seems reasonable to prefer growth charts that are 
based on sonographic EFW over those that are based on birth weight. 
Ultrasound-based growth charts are more difficult and expensive to 
develop, as they are usually based on data from prospective longi-
tudinal studies where women undergo several sonographic weight 
estimations during pregnancy. However, these charts do not share 
the limitation of birth weight-based charts, described above, and 
are thus more likely to reflect the optimal fetal growth throughout 
pregnancy (Figure 2). Another reason why ultrasound-based charts 
should be preferred is that the measure used during pregnancy 
to assess fetal growth is sonographic EFW; it is therefore more 
appropriate to compare it to charts based on the same measure 
(i.e. sonographic EFW) rather than to charts based on birth weight. 
Some of the commonly used ultrasound based charts are presented 
in Figure 2.193
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6.4.3  |  Universal versus customized charts
One final distinction is between universal and customized growth 
charts, which represent a spectrum of approaches towards the 
similarity of the genetic growth potential of different fetuses 
across the world. At one end of this spectrum there are universal 
charts that are based on the assumption that under optimal condi-
tions, all fetuses are expected to have the same growth potential, 
irrespective of their country of origin or race and that the only 
reason for the differences currently observed between different 
countries or races are purely due to environmental factors, such 
as malnutrition and environmental toxins. These ultrasound-based 
charts are developed through multicenter, multinational, prospec-
tive longitudinal studies, where data on sonographic fetal growth 
from multiple countries are pooled into a single international 
universal chart. The best examples of such universal charts are 
the recently published Intergrowth-21st194-196 and World Health 
Organization (WHO) charts.197
Others, however, believe that the variation in fetal growth 
between countries and races is not solely the result of environ-
mental factors. Instead, it is suggested that genetic variation in 
growth potential contributes to the observed differences in fetal 
growth between race groups, and that race-specific charts should 
therefore be preferred over universal charts. Examples of such 
race-specific charts are the National Institute of Child Health and 
Human Development (NICHD) charts which include separate charts 
for white, black, Hispanic, and Asian women,198 and the recently 
published PRB/NICHD customized standard for African American 
women.199
According to the third approach, growth charts should be 
adjusted not only for maternal race but also for other physiologic 
factors that are thought to determine fetal growth potential, such 
as maternal height, weight, parity, and fetal sex. One such example 
is the Gestation Related Optimal Weight (GROW) software for cus-
tomized growth percentiles.200,201
At the other end of the spectrum is the individualized growth 
assessment (IGA) approach, which is based on estimation of the 
growth potential of the individual fetus, calculated from the second- 
trimester growth velocity of that fetus. These estimates are used 
to generate individualized trajectories that are used to interpret 
fetal growth during the third trimester (https://igap.resea rch.bcm.
edu).202–204 While compelling, this approach requires earlier ultra-
sound exams during pregnancy, as well as appropriate software, and 
is therefore challenging at present for the purpose of FGR screening 
in the general population, and especially in low-resource settings.
6.4.4  |  Description of commonly available charts
The 10th percentile curves of some of the charts described above 
are compared in Figure 2. The Hadlock chart (1991), one of the most 
commonly used growth charts, is an ultrasound-based standard. It 
is based on a cohort of 392 low-risk, primarily white women from 
Texas. The Alexander chart (1996) is based on over 3 million single-
ton live births in the USA and is included as an example of a birth 
weight-based reference to illustrate their limitation, which is the 
underestimation of optimal fetal growth during the preterm period.
The goal of the Intergrowth-21st project (2014) was to develop 
a universal ultrasound-based prescriptive growth chart. This was a 
prospective longitudinal study of 4321 low-risk women from eight 
centers located in eight high- and middle-income countries.194 The 
study had strict inclusion and exclusion criteria to ensure that partic-
ipants were not exposed to environmental factors known to affect 
fetal growth, and it therefore aimed to reflect optimal fetal growth. 
Based on predetermined criteria, the authors concluded that the dif-
ferences between participants from different countries in measures 
of skeletal growth (crown–rump length and head circumference) 
were similar enough to justify pooling the data, and they therefore 
generated a single universal chart. No information was provided on 
the differences between countries with respect to measures such 
as fetal weight estimation and abdominal circumference, which are 
used in clinical practice to detect FGR and are known to be associ-
ated with adverse perinatal outcomes. Interestingly, there were con-
siderable differences in birth weight between infants from different 
countries, even in this highly selected group of women free from 
the negative influence of environmental factors known to affect 
fetal growth. For example, the mean birth weight at term in India 
was 2.9 kg, which was approximately 600 g lower than the mean 
birth weight in the UK (3.5 kg).195 These differences have led some 
to question the validity of the pooled chart and of the hypothesis 
F I G U R E  2  Comparison of the 10th percentile curves of common 
growth charts. Key: Hadlock: ultrasound-based chart193; NICHD, 
National Institute of Child Health and Human Development 
chart198; IG21, Intergrowth-21st chart196; WHO, World Health 
Organization chart197 Alexander: birth weight-based chart.192 
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that underlies the Intergrowth-21st project.205,206 As demonstrated 
in Figure 2, the 10th percentile of the Intergrowth-21st chart is 
significantly lower throughout gestation than most other ultra-
sound-based standards.
At around the same time, the results of the NICHD growth study 
(2015) were published.198 The overall design of this study was similar 
to that of the Intergrowth-21st study. It was a prospective longitudi-
nal study of 2334 low-risk women from 12 centers in the USA. The 
authors found substantial differences in fetal weight between dif-
ferent race groups, and therefore developed separate race-specific 
growth charts for white, black, Hispanic, and Asian women. The 10th 
percentile of the NICHD growth chart for white women is included 
as an example in Figure 2.
The WHO fetal growth charts were published in 2017.197 Similar 
to the Intergrowth-21st project, this study aimed to develop a pre-
scriptive universal chart to extend the previously published WHO 
child growth standard 207 to the fetal period. The design of this 
study was also similar to that of Intergrowth-21st—a prospective 
longitudinal study of 1387 low-risk women from 10 centers in 10 
high- and middle-income countries. Despite this, the results of the 
WHO study differed from those of Intergrowth-21st in two aspects. 
First, the 10th percentile of the WHO chart is considerably higher 
than the Intergrowth-21st chart, and is in fact almost identical to the 
10th percentile of the Hadlock standard (Figure 2). Second, unlike 
Intergrowth-21st, the investigators of the WHO study found sub-
stantial differences in fetal growth between the various countries, 
and concluded that “…populations, even under optimal nutritional 
conditions and environment, vary and that fetal growth varies and 
should be considered when the WHO fetal growth charts or any 
growth references are applied”.208 They expressed concern that use 
of a universal chart carries a risk of misclassification of FGR,209-211 
and recommended that their chart should be adjusted in each coun-
try to the local population.
The benefit of customized charts remains a matter of debate. 
The GROW software incorporates certain factors that are believed 
to determine fetal growth potential (maternal race, height, weight, 
parity, and fetal sex) to calculate the predicted optimal (customized) 
weight at 40 weeks for each individual fetus.200,201 The customized 
fetal growth curve is then determined retrospectively, based on a 
proportionality growth function derived from the ultrasound-based 
Hadlock standard.193 The use of customized charts is appealing, 
especially in the setting of ethnically mixed populations where their 
use has been shown to decrease over- and underestimation of FGR 
rates in certain race groups.212 A large number of studies investi-
gated the association of customized charts with adverse pregnancy 
outcomes compared with other birth weight- and ultrasound-based 
charts, with conflicting results. Several studies found that custom-
ized charts performed better at predicting stillbirth and adverse 
neonatal outcomes,66,201,211,213-216 while others found no benefit 
and concluded that the benefit reported by others is merely because 
they are based on an ultrasound-based chart and are thus more 
likely to reflect optimal fetal growth, while the act of customization 
has a minimal contribution to the stronger association with adverse 
outcome.217-219 Another criticism is that the GROW approach 
assumes that all fetuses follow the same growth trajectory (which 
is derived from the Hadlock chart)—an assumption that may not be 
true. Finally, it has been suggested that the required adjustment 
for multiple factors may be too complex for low-resource countries 
and, in that setting, a simple adjustment to only one factor—mean 
birth weight at 40 weeks in the local population—is as predictive 
for adverse perinatal outcomes as the fully customized GROW 
charts.220 It may thus be reasonable for care providers to compare 
the performance of customized growth charts in their population 
with that of noncustomized charts (as discussed below), especially 
in regions or countries with a mixed population where the benefit of 
customization is expected to be greatest.
6.4.5  |  How to choose the best chart
The conflicting results and conclusions regarding the growth charts 
described above have led to an ongoing debate about the best 
approach (i.e. universal versus customized charts), as well as to con-
siderable confusion among care providers over which chart they 
should be using in their local population.
The FIGO Safe Motherhood and Newborn Health Committee 
recently published a position paper on the choice of reference 
charts for fetal growth and size at birth.3 In that paper, the commit-
tee reviewed in detail the commonly available charts and the avail-
able data on their predictive accuracy. The main conclusions were 
as follows: (1) local or regional charts are likely to be best to iden-
tify the 10th percentile of infants at highest risk, given that univer-
sal charts such as Intergrowth-21st are likely to under detect SGA 
fetuses in high-resource countries and, at the same time, over detect 
SGA in low- and middle-income countries; (2) as an alternative, uni-
versal standards such as Intergorwth-21st and WHO may be used 
with locally adjusted thresholds (e.g. 3rd or 5th percentile in low- 
or middle-income countries versus 15th or 20th percentile in high- 
income countries) to avoid under or overdetection of SGA; and (3) 
when assessing fetal size antenatally by ultrasound, fetal (i.e. ultra-
sound-based) charts should be used rather than birth weight-based 
charts. We fully endorse and support these recommendations.
Furthermore, we as well as others,160,208 believe that the deci-
sion on which chart to use can be further based on a comparison of 
performance of the various charts in the population of interest, using 
a local data set. This can be achieved by the following approaches: 
(1) statistical validation: finding the chart that matches best the dis-
tribution of fetal weight in low-risk pregnancies in the local popu-
lation. That is, identifying the chart that when applied to the local 
population yields weight percentiles that follow a normal distribu-
tion centered at approximately the 50th percentile, and identifies 
approximately 10% of the low-risk population as being below the 
10th percentile and above the 90th percentile, and approximately 
5% of the population as being below the 5th percentile and above 
the 95th percentile. An example of this approach is provided in 
Figure 3; (2) outcome-based validation: finding the chart for which 
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the diagnosis of SGA has the best predictive value for adverse out-
comes related to FGR..211,221 While this approach seems compelling, 
interpretation of the predictive value of the different charts for ad-
verse outcomes may be challenging, as there is a trade-off between 
detection rate and false positive rate for adverse outcomes.221 Thus, 
charts that are shifted upward (e.g. Hadlock, WHO) would have a 
higher detection rate but also a high false-positive rate, while charts 
that are shifted downward (e.g. Intergrowth-21st) would have a 
lower false-positive rate but would also have a lower detection rate 
for SGA fetuses at risk of adverse outcomes (Figure 4). Finding the 
chart that provides the best balance between these two measures 
requires careful consideration and should be based on a clear defini-
tion of the goals of screening.
6.5  |  How to assess fetal growth in twin gestations
Twin fetuses grow more slowly than singletons, starting from 
28–32 weeks of gestation onward.222-225 At term, approximately 
30%–50% of twins would be identified as SGA (EFW <10th percen-
tile) using singleton growth standards.223,226,227 The mechanisms 
underlying the relative smallness of twins remain unclear. While 
some believe that this represents a pathological phenomenon due to 
failure of the uteroplacental circulation to meet the demands of two 
fetuses (i.e. twins are more likely to be growth restricted due to the 
same mechanism responsible for FGR in singletons),224,228-230 others 
suggest that this represents an early benign physiological adaptation 
of twins to the “crowded” intrauterine environment in an effort to 
delay the onset of labor (by decreasing uterine distension) and gain 
maturation at the expense of size.231 One important implication of 
this question relates to the growth standard that should be used in 
twins. If the slower growth of twins represents FGR, it would be rea-
sonable to use singleton growth standards to identify the small twin 
fetus that, like SGA singletons, may be at increased risk for perinatal 
mortality and morbidity. However, if the relative smallness of twins 
is due to a benign adaptive mechanism, it may be preferable to use 
twin-specific growth charts 223,232-235 to avoid overdiagnosis of FGR 
in twin gestations,63,227 which is associated with increased use of 
resources, ultrasound exams, interventions, and patient anxiety.
F I G U R E  3  Illustration of the statistical validation of two charts in a local population. The left chart shows a good match to the population 
of interest: the distribution of fetal weight percentiles based on this chart follows a normal distribution that is centered at the 50th 
percentile, with approximately 10% of the population below the 10th and above the 90th percentile. The right chart shows a poor fit for 
the population of interest as it is skewed to the right: it overdiagnoses fetuses as large for gestational age and underdiagnoses small-for-
gestational-age fetuses. [Colour figure can be viewed at wileyonlinelibrary.com]
F I G U R E  4  Illustration of the impact of the growth chart chosen 
on the trade-off between detection rate and false-positive rate 
of fetuses at risk of adverse outcome. Charts that are shifted 
upward (light blue dotted line) will have a higher detection rate for 
pregnancies at risk of adverse outcomes (red circles) but would also 
have a higher false-positive rate (i.e. identify normal pregnancies 
[green circle] as being at risk). In contrast, charts that are shifted 
downward (dark blue solid line) will have a lower false-positive rate 
(i.e. identify fewer normal pregnancies [green circle] as being at 
risk) but will also have a lower detection rate for pregnancies at risk 
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Most current guidelines do not provide clear recommendations 
as to which type of charts should be used to monitor the growth of 
twins,143,236,237 while other guidelines specifically recommend the 
use of singleton-based charts 238 or twin-specific charts.239 As a 
result, singleton-based standards are used by default in most centers 
to assess the growth of twins. However, recent data provide sup-
port to the hypothesis that the relative smallness of twins is a benign 
adaptive mechanism and, therefore, for the use of twin-specific 
charts. For example, several studies suggest that the slower growth 
of twins is the result of differences in programming that is deter-
mined as early as the first trimester..229,240-243 In addition, it was 
found that the use of twin-specific (versus singleton-based) charts 
was associated with a marked decrease in the rate of twins classi-
fied as SGA, without affecting the detection rate of stillbirth, sug-
gesting that twin-specific charts can be used safely.227,244,245 Similar 
findings were reported in studies that investigated the association 
between the type of chart used (twin versus singleton charts) and 
other outcomes such as perinatal complications and long-term mor-
bidity.246,247 Studies that investigated placental pathology findings 
reported that SGA twins (based on singleton charts) are less likely 
to have placental histopathological evidence of placental insuffi-
ciency when compared with SGA singletons.248,249 In another recent 
study on the association between SGA and pre-eclampsia, it was 
found that in contrast to singletons, the diagnosis of SGA in twins 
based on singleton charts was not associated with a greater risk of 
pre-eclampsia, while the association of SGA in twins diagnosed using 
twin-specific charts had the same magnitude of association with 
pre-eclampsia to that observed between SGA and pre-eclampsia 
in singletons.63 Overall, these findings provide support to the 
hypothesis that the relative smallness of twins is less likely to be the 
result of placental insufficiency and, thus, less likely to reflect true 
growth restriction. Based on that, we believe that it seems reason-
able to use twin-specific charts for the assessment of fetal growth 
in twin gestations, as this has the potential to avoid overdiagnosis of 
FGR and the consequences associated with this diagnosis.246 This 
approach is supported by the recent guidelines of the International 
Society of Ultrasound in Obstetrics and Gynecology (ISUOG).239 Of 
note, the diagnosis of FGR in twin gestations should also take into 
consideration intertwin size discordance, especially in the case of 
monochorionic placentation.250
6.6  |  Recommendations






1. Symphysis–fundal height is a simple and inexpensive tool that can be used as the primary screening 
strategy for FGR in low-risk pregnancies in both low- and high-resource settings.
⊕⊕⊕○ Strong
2. There is no evidence to support routine third-trimester ultrasound for the detection of FGR, as this practice 
has not been shown to be associated with improved perinatal outcomes.
⊕⊕⊕⊕ Strong
3. The choice of the equation used for sonographic fetal weight estimation may be based on validation within 
the local population. If this information is not available, we recommend that the following equation of 
Hadlock (based on head circumference [HC], abdominal circumference [AC], and femur length [FL]) should 
be used 2: Log10 weight =1.326 – 0.00326*AC*FL + 0.0107*HC + 0.0438*AC + 0.158*FL
⊕⊕⊕○ Strong
4. Growth standards that are based on sonographic fetal weight estimation should be preferred over growth 
references and over charts that are based on birth weight.
⊕⊕⊕○ Strong
5. We support the recommendation of the FIGO Safe Motherhood and Newborn Health Committee that local 
or regional growth charts should be preferred over universal charts.3 Alternatively, universal standards 
may be used with locally adjusted thresholds to avoid under- or overdetection of FGR.
⊕⊕⊕○ Strong
6. The decision regarding which growth chart to use may be further guided by comparing the performance of 
the various charts in the population of interest, using local data sets.
⊕⊕○○ Weak
7. Based on the available evidence it seems reasonable to use twin-specific charts for the assessment of fetal 
growth in twin gestations as this has the potential to avoid overdiagnosis of FGR in this population.
⊕⊕○○ Weak
8. In twin gestations, the diagnosis of FGR should also take into consideration intertwin size discordance, 
especially in the case of monochorionic placentation.
⊕⊕⊕⊕ Strong
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7  |  WHAT KIND OF INVESTIGATIONS 
SHOULD BE PERFORMED WHEN FETAL 
GROW TH RESTRIC TION IS SUSPEC TED?
Once FGR is suspected, a systematic investigation should be per-
formed aimed at identifying the underlying etiology for fetal small-
ness, with the most important reasons being constitutional SGA, 
placental dysfunction, and fetal conditions such as genetic or infec-
tious disorders. Establishing the most likely etiology is essential to 
allow for proper counseling, surveillance, and interventions. The 
investigation should consist of detailed history, evaluation of screen-
ing test results for trisomy 21 and biochemical markers, detailed 
sonographic assessment for structural anomalies and Doppler stud-
ies, and additional testing directed at genetic or infectious etiologies 
when they are suspected.
7.1  |  Detailed history
A detailed maternal and family history is essential to correctly iden-
tify the etiology of FGR. This should include information on maternal 
age, racial/ethnic group, height and weight, nutritional status, socio-
economic status, medications, cigarette smoking and use of recrea-
tional drugs, chronic medical conditions, personal or family history 
suggestive of thrombophilia, genetic disorders or consanguinity, 
obstetric history including birth weight of previous children, and 
confirmation of pregnancy dating by first-trimester ultrasound.143
Advanced maternal age has been associated with FGR, with risk 
increasing for women over the age of 35 years.251,252 Maternal social 
issues, low income, and domestic violence during pregnancy have 
been shown to be associated with low birth weight.253,254 Poor nutri-
tional status due to conditions such as celiac disease 255 and eating dis-
orders is a potentially treatable cause of FGR.256,257 Maternal smoking 
is an important and potentially modifiable risk factor for FGR.258,259
History should also address the risk of congenital fetal infection 
with cytomegalovirus, toxoplasmosis, syphilis, Zika virus, and var-
icella-zoster virus. Relevant questions include a history of febrile 
disease or rash in pregnancy or the periconceptional period, recent 
travel history to endemic areas (e.g. for Zika virus), and frequent ex-
posure to young children (cytomegalovirus) or to domestic animals 
(toxoplasmosis).
Accurate dating of pregnancy is essential for the correct inter-
pretation of estimated fetal size and to avoid a false diagnosis of 
FGR. Determining gestational age based on menstrual history is 
often unreliable.260,261 Therefore, with the exception of pregnan-
cies achieved by assisted reproductive technology, the crown–rump 
length measured at the time of first-trimester ultrasound is the most 
accurate method to date pregnancy, and establishes gestational 
age with a precision of 5 days in 95% of cases.262-265 Crown–rump 
length is most accurate for the purpose of dating when in the range 
of 7–60 mm.266,267 Therefore, confirmation of gestational age based 
on first-trimester ultrasound (when available) should be the first step 
when FGR is suspected. If more than one scan is performed in the 
first trimester, the earliest scan with a crown–rump length of at least 
10 mm should be used.268
7.2  |  Detailed anatomy scan
Detailed anatomy scan should be routinely performed when FGR 
is suspected, especially in cases of early-onset severe FGR. The 
presence of major structural anomalies, soft sonographic markers, 
or disorders of amniotic fluid (e.g. polyhydramnios) may raise the 
possibility of chromosomal, subchromosomal, or single gene abnor-
malities as the cause of FGR.269,270 The presence of very shortened 
fetal long bones (shorter than –2SD and especially –4SD below the 
mean) should raise the possibility of skeletal dysplasia and indicates 
targeted genetic assessment.271-273 Attention should also be given 
to findings that are associated with congenital infections, especially 
in women with a relevant history, as described above. Examples of 
such sonographic findings include small head circumference, ven-
triculomegaly, brain or liver calcifications, periventricular hypere-
chogenicity, cortical brain malformations, echogenic bowel, hydrops, 
or placentomegaly.40,274
7.3  |  Doppler studies
Doppler assessment is an integral part of the diagnostic process and 
management of FGR. The presence of abnormal Doppler findings in 
the uterine, umbilical, or middle cerebral arteries is highly suggestive 
of placental dysfunction as the underlying etiology of FGR. A more 
detailed description of the different types of Dopplers studies and 
their application in monitoring and timing of delivery in pregnancies 
complicated by FGR is provided in section 8 (Management of FGR).
It should be noted that umbilical artery Doppler findings may 
be normal in the early stages of placental FGR. Therefore, normal 
umbilical artery Doppler studies do not rule out placental dysfunc-
tion, and therefore serial monitoring is recommended in all cases of 
suspected FGR.275,276 At the same time, abnormal umbilical artery 
Doppler is not pathognomonic of placental dysfunction, as certain 
genetic conditions (e.g. triploidy) may mimic early-onset placental 
FGR, including the presence of abnormal umbilical artery Doppler, 
most likely due to concomitant placental insufficiency secondary to 
the abnormal placental karyotype.34,277-279 In contrast to umbilical 
artery Doppler, uterine artery Doppler is less likely to be abnormal 
among fetuses with FGR and abnormal karyotype, and should there-
fore be considered to be more specific for primary placental FGR, 
especially in the presence of abnormal angiogenic markers in mater-
nal blood.34,107,280
7.4  |  Additional testing
Screening for congenital infections should be offered when FGR is 
suspected, especially in cases of early-onset FGR or when infection 
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is possible based on history of ultrasound findings. Testing should 
be focused on cytomegalovirus and toxoplasmosis, but may also 
include rubella, varicella, and syphilis in cases at high risk for these 
infections. Testing for Zika virus and malaria should also be consid-
ered in the relevant travel history or location context. However, it 
should be noted that interpretation of serology results may be chal-
lenging due to limited specificity and cross-reactivity of some of the 
assays, especially when baseline serology results prior to pregnancy 
or from early pregnancy are not available.281 When fetal infection 
is highly suspected based on serology results or clinical findings, 
further testing should be offered by means of amniocentesis for 
the detection of viral DNA in the amniotic fluid using polymerase 
chain reaction. In these cases, amniocentesis should be delayed until 
after 21 weeks of gestation and at least 6–8 weeks following the 
estimated onset of maternal infection to minimize the risk of false-
negative results.274,282
Genetic consultation and genetic testing by amniocentesis 
should be offered to women with FGR, especially in cases of ear-
ly-onset or severe FGR (<3rd percentile), co-presence of sono-
graphic findings (such as structural anomalies, soft markers, or 
polyhydramnios), and the absence of obvious signs of placental 
dysfunction such as abnormal uterine or umbilical artery Doppler. 
In addition, women should be counselled about the risk of a genetic 
etiology even in the presence of “isolated” FGR (i.e. without associ-
ated fetal anomalies).37,270,283-285 A recent meta-analysis of 10 stud-
ies found that in cases of isolated FGR, chromosomal microarray had 
an incremental yield of 4% (95% CI, 1%–6%) over karyotyping: 17 of 
376 fetuses with isolated FGR and normal karyotype had significant 
findings in microarray, most commonly 22q11.2 duplication, Xp22.3 
deletion, and 7q11.23 deletion. The incremental yield of microar-
ray over karyotyping was even higher at 10% (95% CI, 6%–14%) in 
the presence of associated fetal malformations.35 Based on these 
data, it seems reasonable to offer amniocentesis with karyotype and 
microarray analysis (when available) to women with FGR, with the 
decision based on factors such as ultrasound findings, gestational 
age, lack of evidence of placental dysfunction, and whether the re-
sults of the amniocentesis would affect management. These data 
also suggest that the temptation to substitute amniocentesis by non-
invasive prenatal testing (NIPT) using cell-free fetal DNA analysis in 
this context should be strongly resisted.
7.5  |  Recommendations






1. Women with suspected FGR should undergo systematic assessment that includes the following: (1) detailed 
history; (2) detailed sonographic assessment for structural anomalies, soft markers, and sonographic signs 
related to fetal infection; (3) Doppler studies that include at least the umbilical artery and, when available, 
also the uterine and middle cerebral arteries; and (4) maternal screening for relevant congenital infections, 
which should be focused on cytomegalovirus and toxoplasmosis, but may also include rubella, herpes, 
syphilis, malaria, and Zika virus in cases at high risk.
LRS  The extent of investigation may be limited by available resources. Assessment should include 
screening for infections such as malaria and Zika virus in endemic areas.
⊕⊕⊕⊕ Strong
2. Confirmation of gestational age should be the first step when FGR is suspected. With the exception of 
pregnancies achieved by assisted reproductive technology, first-trimester crown–rump length is the most 
accurate method to date pregnancy when in the range of 7–60 mm. If more than one scan is performed in 
the first trimester, the earliest scan with a crown–rump length of at least 10 mm should be used.
LRS  In low-resource settings, dating may need to be based on menstrual history or symphysis–fundal 
height.
⊕⊕⊕⊕ Strong
3. Amniocentesis for karyotype (as well as microarray and polymerase chain reaction for infectious agents 
when available) should be offered to women with suspected FGR, especially in cases with early-onset 
severe (estimated fetal weight <3rd percentile) FGR, in the presence of sonographic findings associated 
with genetic or infectious etiologies, no obvious signs of placental dysfunction, and when the findings are 
likely to affect management.
LRS  The availability of genetic testing may be limited by available resources.
⊕⊕⊕○ Strong
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8  |  MANAGEMENT OF PREGNANCIES 
WITH FETAL GROW TH RESTRIC TION
Management of pregnancies with FGR depends in part on the results 
of the investigation described in section 7. In cases of fetal abnor-
malities (genetic or infectious) the management (expectant versus 
pregnancy termination) should be individualized based on the nature 
of the disorder, the expected prognosis, gestational age, parental 
wishes, and local policies.
The most common underlying etiology of FGR is placental dys-
function. In early-onset FGR (<32 weeks), increased resistance in 
umbilical artery Doppler is the primary rate-limiting step to sub-
sequent deterioration of cardiovascular and biophysical param-
eters.286-292 The primary management challenge arises from the 
risk of fetal deterioration and stillbirth in pregnancies undergoing 
surveillance versus the neonatal morbidity and mortality associ-
ated with preterm delivery.68,293-297 In late-onset FGR (≥32 weeks), 
cardiovascular deterioration in response to fetal hypoxia is pre-
dominantly confined to the cerebral circulation with little umbilical 
artery Doppler changes.289,291,292,298 Pregnancies complicated by 
late-onset FGR are major contributors to adverse perinatal out-
come attributable to FGR because of misdiagnosis and challenges in 
detecting deterioration during fetal surveillance.299,300
There is no effective antenatal treatment for placental dys-
function and therefore once FGR has been identified, the principal 
management steps are institution of fetal surveillance and deter-
mination of appropriate thresholds for delivery. Perinatal outcome 
in early-onset FGR is improved when pregnancies are managed in 
a high-level fetal medicine and neonatology unit utilizing a uniform 
management protocol.301 Likewise, the optimal management set-
ting for late-onset FGR is a unit that has access and experience in 
interpretation of surveillance tests, together with an appropriate 
level neonatal unit. The recommendations for monitoring, tim-
ing and mode of delivery, and potential treatments for placenta- 
 mediated FGR are described below and summarized in Table 1 and 
Figure 5.
8.1  |  Monitoring
The primary goal of fetal monitoring is prevention of stillbirth by 
detection of fetal deterioration that precedes irreversible compro-
mise. To achieve this goal, monitoring tests need to be accurate 
in identifying fetal risks that favor delivery and, for pregnancies 
where delivery thresholds are not met, follow-up monitoring needs 
to be frequent enough to provide a safety net against unanticipated 
deterioration or stillbirth. Fetal surveillance tests include mater-
nal monitoring of fetal movements, cardiotocography, ultrasound 
evaluation of amniotic fluid volume and fetal activity, and Doppler 
ultrasound of the fetal arterial and venous circulations. With pro-
gressive compromise, abnormal fetal activity and fetal heart rate 
patterns are observed, independent of gestational age at diagno-
sis of FGR.288,292,302-304 In contrast, cardiovascular manifestations 
of fetal compromise are driven by placental blood flow resistance 
in the umbilical artery, and therefore differ significantly between 
early- and late-onset FGR.286,289-291,298,299 The surveillance tests 
that have been evaluated in the management of FGR pregnancies 
are described below.
8.1.1  |  Fetal movement counting
Fetal activity is established from the first trimester onward and 
as gestational age advances becomes organized into coordinated 
behavioral states. Progressive fetal hypoxemia is accompanied by a 
reduction of fetal activity that can be perceived most accurately by 
the mother when she is lying down and paying focused attention to 
fetal movements.305 Decreased fetal movement is often defined as 
less than 10 movements in 2 hours during focused maternal count-
ing.306 Although reports on whether quality improvement tools 
to promote awareness and management of reduced fetal move-
ments can effectively decrease the risk of stillbirth have been con-
flicting, most of these interventions were focused on unselected 
populations rather than in pregnancies with suspected FGR.307-309 
Given that fetal movement counting is a simple and inexpensive 
tool that may provide a safety net between scheduled outpatient 
monitoring visits, it seems reasonable to use movement counting 
as an adjunct to monitoring in FGR. The mother should be provided 
with clear behavioral instructions and confirmatory monitoring 
should be performed for patients presenting with decreased fetal 
movements.305,308
8.1.2  |  Fetal heart rate monitoring
Fetal heart rate monitoring is universally recommended to moni-
tor pregnancies complicated with FGR.134,310-312 Antepartum car-
diotocography (CTG), also known as a nonstress test (NST), can be 
performed as a standalone evaluation or in conjunction with meas-
urement of amniotic fluid volume (modified biophysical profile), or a 
five-component biophysical profile (BBP).
Some heart rate characteristics reflect fetal oxygenation, ges-
tational age, and maturational state of the nervous and cardiovas-
cular systems. The normal heart rate baseline is between 110 and 
160 beats per minute (bpm) and decreases with advancing gestation. 
Periodic accelerations of fetal heart rate (FHR) usually coincide with 
fetal movements, are observed from the early second trimester, and 
increase in magnitude and duration with advancing gestation. These 
are defined as increases in FHR over the baseline of at least 15 bpm 
and 15 seconds’ duration. Two or more of these accelerations de-
fine a “reactive” pattern. Recognizing that the frequency of reactiv-
ity increases from 50% at 24–28 weeks to 85% at 28–32 weeks of 
gestation, criteria of greater than or equal to 10 bpm amplitude and 
greater than 10 seconds’ duration are recommended at earlier ges-
tational ages.313-316 A “nonreactive” FHR pattern is one that does 
not display accelerations over an observation period of 40 minutes. 
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In addition to reactivity, FHR patterns display “variability”—the 
average oscillations in the FHR signal, evaluated in bpm in 1-min-
ute windows. Reduced variability appears later than absent reactiv-
ity in the process of progressive fetal hypoxia. It reflects reduced 
sympathetic–parasympathetic activity, secondary to diminished 
brainstem oxygenation.
The FHR pattern reflects fetal oxygenation and acid-base sta-
tus at the time of evaluation but does not predict deterioration 
TA B L E  1  Recommendations for monitoring, timing, and mode of delivery in cases with suspected fetal growth restriction.
Findings Risk of stillbirth Suggested monitoringa  Timing and mode of deliveryb 
SGA (EFW at 3rd–9th 
percentile, normal fluid and 
Doppler studies)
Low • Doppler (UA, MCA) every 
1–2 weeks
• Growth every 2 weeks
• At ≥37 weeks consider BPP/NST 
1–2 times per weekc 
• 37–39 weeks
• Mode of delivery: induction
Uncomplicated FGR at <3rd 
percentile (normal fluid 
and Doppler studies)
Low • Doppler (UA, MCA) 1–2 times per 
week
• Growth every 2 weeks
• At ≥37 weeks consider BPP/NST 
1–2 times per weekc 
• 36–38 weeks
• Mode of delivery: induction
FGR with mild abnormalities:
• Early Doppler changes:
a. UA PI >95th percentile, 
or
b. MCA PI <5th percentile, 
or
c. CPR <5th percentile, or
d. UtA PI >95th percentile
• Oligohydramnios
• Suboptimal interval growth
• Suspected pre-eclampsia
Low • Consider inpatient monitoring
• Consider steroids for fetal lung 
maturation
• BPP/NST 1–2 times per week
• Doppler (UA, MCA, DV) 1–2 
times per week
• Growth every 2 weeks
• 34–37 weeks
• Mode of delivery: cesarean 
section or induction
FGR with umbilical artery 
AEDV/REDV
• Overall risk of stillbirth:332
a. AEDV: 6.8%, OR 3.6 [2.3–5.6]
b. REDV: 19%, OR 7.3 [4.6–11.4]
• Risk of stillbirth with strict 




• Median time for deterioration:
a. AEDV: 5 days
b. REDV: 2 days
• Inpatient monitoring
• Steroids for fetal lung maturation
• BPP/NST 1–2 times per day
• Doppler (UA, MCA, DV) every 
1–2 days
• Growth every 2 weeks
• AEDV: 32–34 weeksd 
• REDV: 30–32 weeksd 
• Mode of delivery: cesarean 
section
FGR with abnormal ductus 
venosus Doppler
• Overall risk of stillbirth332: 20%, 
OR 11.6 (6.3–19.7)
• Risk of stillbirth with strict 
monitoring protocol with a safety 
net:343
a. Elevated DV PIV: 2%
b. Absent-reverse a-wave in DV: 
4%
• Inpatient monitoring
• Steroids for fetal lung maturation
• BPP/NST twice per day
• Daily Doppler
• 26–30 weeksd 
• Mode of delivery: cesarean 
delivery
Abbreviations: AEDV/REDV, absent or reversed diastolic velocity in the umbilical artery; BPP, biophysical profile; CPR, cerebroplacental ratio; DV, 
ductus venosus; FGR, fetal growth restriction; MCA, middle cerebral artery; NST, nonstress test; OR, odds ratio; PI, pulsatility index; PIV, pulsatility 
index for veins; SGA, small for gestational age; UA, umbilical artery; UtA, uterine artery.
aMonitoring should be based on integration of multiple modalities (Doppler, BPP, NST). 
bAbsolute indications for delivery at any gestational age and birth weight combination that are considered to be viable include: BPP or NST 
abnormalities or severe pre-eclampsia with uncontrolled hypertension or end-organ damage (section 8.2.3). In addition, timing of delivery should be 
individualized based on factors such as parental decision regarding threshold for intervention. 
cThere is lack of evidence on the appropriate test to predict the risk of fetal deterioration and on the optimal monitoring strategy in cases of 
uncomplicated SGA fetuses, especially at term. Given this, there are differences in practice in various regions of the world regarding use of BPP/NST 
for fetal monitoring in this context, and some of the authors of these guidelines do not use BPP or NST for monitoring of fetuses with uncomplicated 
SGA as long as Doppler studies are normal. We suggest that the decision regarding use of BPP/NST should be based on local practices, the risk 
profile of the local population, and the available resources in each particular setting. 
dTiming should be individualized based on local neonatal outcomes. Before 26 weeks, careful and shared decision making with the parents and 
neonatology team is recommended. 
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in FGR. In unselected pregnancies the rate of stillbirth in the 
week following a reactive CTG/NST is 1.9/1000 (negative pre-
dictive rate of 99.8%).317 Without any additional information, the 
empirically recommended minimum frequency is twice weekly 
CTG/NST. The frequency may be increased when evaluation of 
amniotic fluid or Doppler parameters indicate a more advanced 
degree of fetal compromise and delivery criteria have not yet 
been met. A nonreactive CTG/NST has low specificity for hypoxia 
and requires additional tests to determine fetal status and dis-
tinguish FHR pattern variations caused by fetal behavior, while 
reduced variability is a much stronger predictor of central ner-
vous system hypoxia.
8.1.3  |  Computerized fetal heart rate monitoring
Some professional societies recommend computerized fetal heart 
rate monitoring (cCTG) as the preferred modality to analyze CTG/
NST tracings.134,308 Inconsistency in visual assessment, particularly 
FHR variability, is a major contributor to interobserver variations in 
interpretation of CTG/NST tracings.318 cCTG evaluates FHR param-
eters such as baseline, accelerations, decelerations, and variability 
in an objective and quantifiable way. The Sonicaid cCTG system 
(Huntleigh Healthcare, Cardiff, UK) provides the parameter “short-
term variation” (STV) in milliseconds, while others quantify variabil-
ity in a more traditional way in bpm.319 In contrast to visual FHR 
analysis, cCTG decreases observer variability and allows longitudinal 
numerical analysis of variability.320
FHR variability increases with gestational age; after 29 weeks of 
gestation, below 4.0 ms or below 3.0 ms meet criteria for reduced 
or very low STV, respectively.321 Before 29 weeks of gestation, STV 
below 3.5 ms is considered reduced, and below 2.6 ms is considered 
very low. STV below 3 ms has a 77% positive predictive value for 
fetal acidemia.322,323
Similar to CTG/NST, cCTG does not predict fetal deterioration. In 
early-onset FGR the daily risks for abnormal STV are 4%–5% but are 
unpredictable by additional monitoring tests. Accordingly, CTG/NST 
or cCTG monitoring needs to be performed more frequently than 
Doppler assessments. In patients receiving inpatient monitoring, a 
minimum frequency of daily cCTG/CTG/NST is recommended.320
F I G U R E  5  Delivery criteria for fetal growth restriction. Delivery criteria are based on monitoring with umbilical artery, ductus venosus, 
and middle cerebral artery Doppler at specified gestational ages with traditional nonstress testing or computerized CTG (cCTG) if available. 
Abbreviations: NICU, neonatal intensive care unit; FHR, fetal heart rate; CTG, cardiotocogram; STV, short-term variation; ms, milliseconds; 
EFW, estimated fetal weight; PI, pulsatility index. [Colour figure can be viewed at wileyonlinelibrary.com]
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8.1.4  |  Ultrasound measurement of amniotic 
fluid volume
Professional societies do not recommend inclusion of isolated 
amniotic fluid volume assessment into management decisions for 
FGR. A decrease in amniotic fluid volume can occur as a result of 
fetal oliguria in response to progressive placental dysfunction and 
hypoxia, as well as rupture of membranes.287,288,324 Accordingly, 
additional evaluation is required to determine the significance of 
decreased amniotic fluid volume. Oligohydramnios can be defined 
as an ultrasound measured four-quadrant amniotic fluid index below 
or equal to 5 cm, or a maximum vertical amniotic fluid pocket below 
or equal to 2 cm.325 Use of the latter reduces overdiagnosis of oligo-
hydramnios and is preferred. Oligohydramnios is associated with an 
increased rate of intrapartum FHR abnormalities, need for cesarean 
section, and low 5-minute Apgar scores, but not acidosis at birth.326
8.1.5  |  Biophysical profile scoring
Biophysical profile (BPP) scoring is not universally recommended as 
the primary surveillance tool for FGR and is predominantly utilized 
in Canada and North America where the concept was first devel-
oped for fetal surveillance in the later part of the third trimester. The 
modified BPP refers to combined use of the CTG/NST as a short-
term indicator of fetal acid-base balance and the maximum amniotic 
fluid pocket as an indicator of long-term placental function.327 The 
five-component BPP comprises fetal breathing movements, gross 
body movements, and tone, in addition to CTG/NST and maximum 
amniotic fluid pocket, and therefore includes four indicators of 
short-term acid-base balance.301
The modified BPP is considered abnormal when either the CTG/
NST is nonreactive, or the maximum amniotic fluid pocket is below 
2 cm. The most common reason for an abnormal modified BPP is a 
nonreactive CTG/NST, requiring additional ultrasound observation 
to complete a five-component BPP and determine fetal acid-base 
balance. The BPP is scored over a 30-minute ultrasound observation 
period of the fetus. Fetal breathing movements are considered pres-
ent if one or more episodes of 30 seconds of breathing or hiccups 
are observed. Fetal body movement is present when three or more 
discrete body or limb movements are observed. Fetal tone is pres-
ent when one or more episodes of extension and flexion of the fetal 
extremities are observed. Each component of the BPP receives a score 
of 2 for its presence and 0 for its absence. Scores of 8–10, 6, and 4 or 
less are considered normal, equivocal, and abnormal, respectively.
In unselected pregnancies, the rate of stillbirth in the week fol-
lowing a normal modified or five-component BPP is 0.8/1000 (neg-
ative predictive rate >99.9%). FGR fetuses show a sequential loss of 
heart rate reactivity, breathing movements, gross body movement, 
and tone with decrease in pH.287,288,301,302 In FGR pregnancies, an 
abnormal BPP (score of 4 or less) is associated with an umbilical 
artery pH of less than 7.20, with sensitivity increasing to 100% at a 
score of 0/10.301,302,319
The BPP is a more accurate predictor of fetal acid-base status at 
the time of testing than CTG/NST, with a similar accuracy as cCTG. 
Therefore, a five-component BPP can be used to clarify fetal acid- 
base status when a nonreactive CTG/NST is obtained. The frequency 
of BPP testing is guided by the same principles as timing of fetal heart 
rate testing.
8.1.6  |  Umbilical artery Doppler
Umbilical artery Doppler is universally recommended for monitoring 
of FGR because it assesses the hemodynamic aspect of placental 
dysfunction.134,143,308,310 It is estimated that approximately one-third 
of the villous circulation needs to be damaged before a decrease in 
umbilical artery end-diastolic velocity occurs. Absent or reversed 
umbilical artery end-diastolic velocity corresponds to malperfusion 
of 50%–70% of the villous vascular tree.328 Because elevated villous 
blood flow resistance is predominantly associated with the placental 
pathology found in early-onset FGR, umbilical artery Doppler does 
not reliably predict outcome in late-onset FGR.329-331
The umbilical artery Doppler waveform can be quantified using 
the pulsatility index, or by visual classification of end-diastolic veloc-
ity as absent (AEDV) or reversed (REDV). With increasing degrees 
of placental blood flow resistance, an abnormal umbilical artery 
waveform is defined as either having an elevated pulsatility index, 
AEDV, or REDV. The degree of placental blood flow resistance ele-
vation is the primary factor determining the rate of clinical progres-
sion and the associated risk for fetal deterioration and stillbirth in 
early- onset-FGR.286,289,291,292 When the umbilical artery pulsatil-
ity index is elevated but end-diastolic forward flow is still present, 
the median time interval to additional surveillance abnormalities is 
2 weeks. Once AEDV occurs, cardiovascular deterioration advances 
after a median of 5 days and the weighted odds ratio for stillbirth is 
3.6 (2.3–5.6).286,291,332 When REDV occurs, the median interval for 
further fetal deterioration is 2 days and the weighted odds ratio for 
stillbirth is 7.3 (4.6–11.4).291,331
In patients with normal umbilical artery Doppler, the recom-
mended frequency to repeat Doppler monitoring ranges from weekly 
to every other week. However, when AEDV develops, Doppler sur-
veillance is recommended at minimum twice weekly, and for REDV 
at least three times weekly unless delivery criteria have been met.
8.1.7  |  Cerebral artery Doppler
The majority of professional societies now recommend middle cer-
ebral artery Doppler for monitoring in late-onset FGR. Concurrent 
measurement of the umbilical artery and middle cerebral artery 
pulsatility index allows calculation of the cerebroplacental Doppler 
ratio. Both the cerebroplacental ratio and middle cerebral artery 
pulsatility index decrease as a hemodynamic response to fetal 
hypoxemia and therefore reflect placental dysfunction, even in 
those pregnancies where the villous blood flow resistance is not 
34  |    MelaMed et al.
elevated enough to produce an abnormal umbilical artery pulsatility 
index. Approximately 20% of term SGA fetuses with normal umbili-
cal artery Doppler have a decreased middle cerebral artery pulsatil-
ity index, which is associated with a higher rate of cesarean section 
for intrapartum distress, poor neonatal transition, and adverse 
developmental outcome.333-335 The cerebroplacental Doppler ratio 
is more closely related to fetal hypoxia than its individual compo-
nents,336 but has a similar predictive accuracy for perinatal death, 
fetal distress, or poor neonatal transition as the umbilical artery pul-
satility index.337
Cardiovascular deterioration in late-onset FGR is characterized 
by abnormal cerebral artery Doppler. Therefore, an important role of 
middle cerebral artery Doppler is to provide an estimate of perinatal 
risk in patients with normal umbilical artery Doppler.292,331 Because 
of the higher risk for adverse outcome within 1 week of a decrease in 
middle cerebral artery pulsatility index, it is recommended to utilize 
at least twice weekly surveillance in this setting.
8.1.8  |  Ductus venosus Doppler
The few professional societies that recommend ductus venosus 
Doppler evaluation specify that it should be performed in special-
ized centers that have expertise in the comprehensive perinatal 
management of early-onset FGR.312 The relative forward flow in 
atrial systole in the ductus venosus decreases with worsening pla-
cental function or reduced fetal cardiac function, leading to an 
increase in the pulsatility index for veins, absent, or reversal of the 
a-wave.286,288,291,292,338
Abnormal ductus venosus Doppler is primarily observed in 
early- onset FGR and can provide an estimate of fetal acid-base bal-
ance and the risk of stillbirth. The odds ratio of absent or reversed 
atrial  systolic velocity for an umbilical artery pH less than 7.20 at 
birth is 4.4 (1.2–17.2).339,340 The weighted odds ratio of absent or 
reversed ductus venosus atrial systolic velocity for fetal death is 11.6 
(6.3–19.7).331
Abnormal ductus venosus Doppler also predicts fetal 
decompensation to an abnormal BPP, reduced variability on cCTG, 
or stillbirth. In fetuses with elevated ductus venosus pulsatility 
index for veins but forward flow during atrial systole, the median 
interval to progressive venous Doppler deterioration can be as 
short as 2 days.291 In patients that do not yet meet delivery cri-
teria, ductus venosus Doppler is recommended at minimum twice 
weekly in patients with AEDV and three times weekly when REDV 
is observed.286,291,292,341 When ductus venosus Doppler indices 
increase as a new finding, the frequency of monitoring needs to 
be increased further.
8.1.9  |  Surveillance strategy
Monitoring in FGR pregnancies is intended to prevent fetal com-
promise or stillbirth, and the choice of tests and their timing is 
heavily influenced by gestational age. A robust plan is essential, 
since expectant management with ongoing monitoring, particularly 
in the setting of early-onset FGR, can result in a three to five-fold 
increased stillbirth rate when compared with immediate delivery, 
depending on the degree of cardiovascular compromise that is tol-
erated before triggering delivery.294,342,343 The optimal monitoring 
frequency in FGR has not been determined due to the varying cir-
cumstances of gestational age and severity of FGR. A combination of 
surveillance modalities is needed to accurately determine fetal acid-
base status at the time of testing, as well as allowing anticipation 
of future deterioration.289-292,298,344 The accurate prediction of fetal 
acid-base status is required to prevent unnecessary intervention and 
nonindicated delivery. The anticipation of deterioration informs sub-
sequent monitoring intervals that provide a safety net against unan-
ticipated fetal acidosis and asphyxia. The combination of biophysical 
(CTG/NST, cCTG, BPP) and cardiovascular parameters (umbilical 
artery, middle cerebral artery, and ductus venosus Doppler) is con-
sidered a robust approach for FGR surveillance. Among these mo-
dalities, the combination of CTG/NST and umbilical artery Doppler 
is universally recommended.
There is good evidence that umbilical artery Doppler offers 
sufficient information to determine monitoring frequency in early- 
onset FGR. Although middle cerebral artery Doppler could provide 
additional information in those late-onset FGR pregnancies with 
normal umbilical artery Doppler, this practice has not been evalu-
ated.292,328,329 Based on observational data in term FGR with nor-
mal umbilical artery Doppler, the approximate interval to stillbirth 
in patients with abnormal middle cerebral artery Doppler is 4 days, 
suggesting the need for twice weekly CTG/NST monitoring. In 
the absence of further evidence on the clinical benefit of middle 
cerebral artery Doppler, twice weekly CTG/NST monitoring in FGR 
after 32 weeks of gestation in patients with normal umbilical artery 
Doppler provides the same safety net (Table 1).
When umbilical artery pulsatility index is elevated, weekly 
Doppler is suggested, and when there is AEDV or REDV, more fre-
quent assessment is recommended (Table 1). In early-onset FGR with 
AEDV or REDV, the risk of stillbirth increases when the ductus veno-
sus Doppler or the CTG/NST patterns become abnormal.292,319,340 
However, there is currently no evidence that adjusting the timing of 
monitoring based on ductus venosus Doppler improves outcome. In 
patients with AEDV the stillbirth rate is 0%–1% when at least once 
daily CTG/NST, cCTG, or BPP is performed with predefined delivery 
criteria.341,342 When monitoring is continued to allow for an increase 
in the ductus venosus pulsatility index for veins, the stillbirth rate 
is 2%, and 11% of deliveries occur for abnormal STV, 19% for an 
abnormal BPP, and 22% for FHR decelerations.304,342 When moni-
toring is continued in anticipation of reversal of the ductus venosus 
a-wave velocity, the stillbirth rate is 4%, and 20% of deliveries occur 
for abnormal STV, 29% for an abnormal BPP, and 31% for FHR decel-
erations (Table 1).342,345 This indicates that with ongoing monitoring 
the risk of FHR abnormalities or an abnormal BPP requiring delivery 
cannot be predicted by the ductus venosus Doppler.319,346 Based on 
the regional pattern of practice, this indicates that in patients who 
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are admitted for AEDV, the minimum frequency of CTG/NST or BPP 
should be daily and more frequent with REDV (Table 1).319
8.2  |  Timing of delivery
The timing of delivery in FGR is determined by gestational age, 
severity of FGR, findings of fetal monitoring tests, and maternal 
factors such as pre-eclampsia (Table 1 and Figure 5). Delivery in-
dications can be considered as absolute if they are independent of 
gestational age, and relative if the threshold to deliver based on the 
surveillance findings varies across gestational age.
8.2.1  |  Gestational age-related risks in fetal growth 
restriction
With advancing gestational age there are several important changes 
in the relative risks of delivery versus ongoing surveillance that 
define the delivery thresholds.
From 24–28 weeks of gestation each day of pregnancy pro-
longation results in an estimated 2% decrease in neonatal death, 
as well as major neonatal complications including bronchopul-
monary dysplasia, high-grade intraventricular hemorrhage, and 
surgical necrotizing enterocolitis. The impact of prematurity, 
neonatal weight below 500 g, challenging resuscitation, and 
decreased tolerance for low Apgar scores results in average neo-
natal survival rates below 50% and intact survival below 50% until 
26 weeks.68,298,345,346
Between 28 and 30 weeks of gestation the daily increment in 
survival is approximately 0.7%. After 30 weeks, neonatal survival 
rates exceed 90%,68,296,297 and there is a significant decrease in 
major neonatal complications from approximately 35% at 30 weeks 
to less than 10% at 34 weeks, as well as a decrease in the risk of neu-
rodevelopmental delay for neonates delivered after this time. FGR 
infants delivered prior to 30 weeks have a three-fold higher rate of 
developmental abnormalities and an up to eight-fold increased rate 
of cerebral palsy.10,295
From 34–38 weeks of gestation neonates are more likely to 
require admission to the intensive care nursery but have reduced 
risks of major neonatal complications.347,348 In SGA fetuses that 
remain undelivered after 38 weeks, the risk of stillbirth doubles 
every week and reaches 60/10 000 for pregnancies that continue 
beyond the due date.349,350
8.2.2  |  Gestational age-related 
management strategy
The balance between fetal and neonatal risks defines the pre-
dominant management strategy at different gestational epochs. 
Accordingly, the goal of management shifts from gaining fetal viability 
at 26 weeks to a graded improvement in survival, neonatal morbidity, 
and neurodevelopment by delaying delivery until 34–36 weeks. The 
increase in stillbirth rate in undelivered fetuses increasingly favors 
delivery from 36 weeks onward.
Timing of delivery in FGR has been evaluated in three random-
ized trials. The growth restriction intervention trial (GRIT) random-
ized pregnancies that had abnormal fetal biometry and umbilical 
artery Doppler studies performed as part of clinical management 
into immediate delivery after completion of a course of steroids 
versus delivery when the managing physician was no longer com-
fortable with conservative management.294,295 The monitoring pro-
tocol and delivery criteria were not specified. The trial demonstrated 
that, in the absence of specific criteria, either management approach 
resulted in the same perinatal outcome. Delaying delivery increased 
the risk of stillbirth, while earlier delivery resulted in a higher degree 
of prematurity-related complications that either led to neonatal 
death or an increased risk of developmental delay.
The disproportionate intrauterine growth intervention trial at 
term (DIGITAT) randomized SGA fetuses by several biometry crite-
ria, independent of the umbilical artery Doppler pattern, to induction 
or expectant monitoring between 36 and 41 weeks of gestation.347 
The study demonstrated that, while elective induction did not affect 
neonatal or obstetric outcomes, deliveries prior to 38 weeks resulted 
in a higher rate of admissions to the neonatal intensive care unit.
These trials demonstrate that the relative risk for neonatal com-
plications requires definitive delivery indications until 38 weeks of 
gestation. After that time, delivery for indication of FGR is likely to 
prevent stillbirth in ongoing pregnancies. The continuous decrease 
in neonatal risks requires that delivery indications at early ges-
tational ages occur at a higher threshold for fetal risks than after 
30–32 weeks.
8.2.3  |  Absolute delivery criteria for fetal growth 
restriction (independent of gestational age)
Absolute delivery criteria are findings associated with important 
health risks to the mother or fetus, and therefore require delivery 
without consideration of gestational age (Figure 5).
The fetal biophysical variables are strongly influenced by oxygen 
tension in the regulatory centers. A 30-minute BBP score of 0 or 2, 
or a 60-minute score of 4 indicates a prelabor fetal pH of less than 
7.20 and requires delivery to prevent fetal demise.
Repetitive FHR decelerations, a sinusoidal heart rate, absent 
variability with recurrent late decelerations, or bradycardia predict 
fetal acidemia and poor perinatal outcome and require delivery if the 
causative stimulus cannot be removed. When cCTG is used, a short-
term variation below 2.6 ms is below the 5th percentile irrespective 
of gestational age and requires delivery for its strong association 
with fetal acidemia.
Maternal pre-eclampsia with severe features complicates up to 
30% of FGR pregnancies, with a higher proportion in early-onset 
FGR. In the absence of effective treatment other than delivery, 
pre-eclampsia with uncontrolled severe hypertension, HELLP 
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syndrome (hemolysis, elevated liver enzyme levels, and low plate-
lets), or other evidence of end-organ damage (e.g. oliguria or acute 
renal injury other than proteinuria, pulmonary edema, or eclampsia) 
requires delivery (Figure 5).
8.2.4  |  Relative delivery criteria for fetal growth 
restriction (adjusted for gestational age)
The trial of umbilical and fetal flow in Europe (TRUFFLE) evaluated 
two monitoring strategies and specific delivery criteria in early-
onset FGR, with survival without neurodevelopmental impairment at 
2 years of age as the primary outcome.343 Monitoring with cCTG and 
umbilical artery Doppler was universal in all patients, while ductus 
venosus Doppler was only added in two study arms. Patients were 
randomized to one of three specific delivery criteria: (1) abnormal 
cCTG STV; (2) mild ductus venosus abnormalities; and (3) severe duc-
tus venosus abnormalities with absence or reversal of the a-wave. 
Because patients with ductus venosus Doppler monitoring also had 
FHR monitoring, safety net delivery criteria based on cCTG were also 
applied in these groups. These included STV below 2.6 ms irrespec-
tive of gestational age and below 3.0 ms from 29 weeks onward. In 
addition, umbilical artery Doppler findings were utilized as relative 
delivery criteria from 30 weeks onward for REDV and 32 weeks 
onward for AEDV. The choice of these thresholds is supported by a 
recent meta-analysis that found that in undelivered FGR pregnancies, 
umbilical artery REDV has a 19% stillbirth rate, which exceeds mortal-
ity for neonates delivered from 30 weeks onward, while AEDV carries 
a 6.8% stillbirth risk, which favors delivery due to lower neonatal mor-
tality from 32 weeks onward (Table 1 and Figure 1).332
The TRUFFLE study demonstrated that a predefined manage-
ment strategy produces better outcomes than expected in all FGR 
pregnancies.343 The primary endpoint was less frequently observed 
in patients randomized to deliver for late ductus venosus abnormal-
ity. Overall, cCTG was the most frequent trigger for delivery. In the 
three arms, delivery was based on abnormal STV in 11%–51% of 
participants, and visually apparent FHR decelerations led to delivery 
in 22%–31% of participants. While the strategy of awaiting absent 
or reversed ductus venosus a-wave to determine delivery produced 
the better study outcome, it is noteworthy that the stillbirth rate 
increased four-fold compared with patients who were monitored 
with cCTG and umbilical artery Doppler. In addition, an absent duc-
tus venosus a-wave only triggered delivery in 10% of participants in 
this study arm. The frequency of delivery decisions based on FHR 
abnormalities emphasizes the importance of concurrently monitor-
ing growth-restricted fetuses with more than one modality.
Because cCTG is not universally available, most healthcare pro-
viders need to rely on traditional CTG/NST monitoring. While BPP 
has not been studied in randomized intervention trials in FGR, it 
is an established monitoring tool to verify fetal status in patients 
with a nonreactive tracing. In FGR, an abnormal BPP predicts ab-
normal arterial pH with a similar accuracy to cCTG and is an inde-
pendent delivery trigger at a comparable frequency to cCTG.304,319 
Therefore, it is recommended that in FGR fetuses with nonreassur-
ing CTG/NST not yet meeting the criteria for delivery, a BPP is com-
pleted to establish fetal status. If the expertise is not available to 
perform a BPP, prolongation of the CTG/NST or increase in testing 
frequency may be required to determine if delivery is necessary.
Optimal delivery criteria for FGR presenting after 32 weeks of 
gestation have not been evaluated in a randomized trial and are 
based on expert consensus. Table 1 and Figure 5 summarize the 
management approaches and recommendations for delivery. When 
local neonatal outcomes are consistently more favorable for FGR 
neonates, relative delivery indications may be applied at earlier ges-
tational ages than indicated. For example, improved neonatal sur-
vival may justify delivery for REDV from 30 weeks onward.
8.3  |  Mode of delivery and intrapartum 
considerations
FGR in itself is not an indication for cesarean section. However, pri-
mary cesarean section may be considered in selected cases of severe 
FGR where the likelihood of successful vaginal delivery is low.
Fetuses with placenta-mediated FGR are less likely to tolerate 
the stress associated with labor and are at increased risk of requiring 
intrapartum urgent cesarean section for nonreassuring FHR tracing. 
Therefore, in certain cases of FGR, a trial of labor is highly unlikely to 
be successful and might be associated with fetal risks to the extent 
that a primary cesarean section should be preferred. This depends 
on multiple factors including gestational age, severity of FGR, 
Doppler changes, associated pre-eclampsia, parity, cervical Bishop 
score, and patient preference (Table 1).
In cases of early-onset FGR the main goal is to prolong preg-
nancy and maximize fetal maturation by means of expectant man-
agement under close monitoring until there is evidence of late 
Doppler changes in the umbilical artery (AEDV or REDV), ductus 
venosus alterations, or FHR abnormalities. Therefore, at the point 
when delivery is indicated in cases of severe early-onset FGR, the 
fetus might already be experiencing some degree of hypoxia or aci-
dosis,291 in which case the likelihood of the fetus tolerating labor is 
low and the rate of cesarean section has been reported to be greater 
than 80%.351 In addition, labor induction in general is less likely to be 
successful during the preterm period.352,353 For these reasons, pri-
mary cesarean section is usually the preferred option when delivery 
is indicated in cases of severe early-onset FGR. 354
In contrast, late-onset FGR is usually less severe and fetal hypoxia 
or acidosis is less likely to be present at the time when delivery is 
indicated. Indeed, in the DIGITAT trial the rate of vaginal delivery 
was greater than 80% in pregnancies induced for SGA with normal 
umbilical artery Doppler after 36 weeks of gestation.347 This obser-
vation suggests that most term SGA fetuses with normal umbilical 
artery Doppler can tolerate labor and that the presence of late-onset 
FGR in the absence of additional factors does not preclude induc-
tion of labor. Several studies have tried to individualize the decision 
regarding mode of delivery through the development of models for 
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the prediction of urgent cesarean section in women with late-onset 
SGA undergoing labor induction. The factors that were most pre-
dictive of urgent cesarean section were gestational age, severity of 
SGA (EFW <3rd percentile), cerebral Doppler (middle cerebral artery 
and cerebroplacental ratio), and Bishop score.355,356 For example, in 
a large cohort study of 509 women undergoing labor induction for 
late-onset SGA, the predictive model had a positive predictive value 
of 36% and a negative predictive value of 89% for urgent cesarean 
section for nonreassuring fetal state.355 Thus, although this informa-
tion can be helpful for patient counselling regarding mode of deliv-
ery and may reassure women with none of these risk factors of the 
high likelihood of a successful trial of labor (nearly 90%), the positive 
predictive value of these models (i.e. a risk of cesarean section in the 
range of 30%–40%) is not high enough to preclude a trial of labor 
even when these risk factors are present.
The optimal approach for cervical ripening in women undergo-
ing induction for FGR remains unclear. In a recent meta-analysis of 
12 trials on cervical ripening in pregnancies complicated by SGA or 
FGR, the authors concluded that mechanical methods (such as bal-
loon catheters) seem to be associated with a lower risk of cesarean 
section and intrapartum complications compared with alternatives 
such as dinoprostone.357 Given these data, it seems reasonable to 
prefer balloon catheter over prostaglandin preparations, when pos-
sible, for cervical ripening in pregnancies with suspected FGR. If 
prostaglandin agents are used, a reversible method (e.g. dinopros-
tone vaginal insert) should be preferred.
During labor, continuous FHR monitoring is recommended. 
Delivery should take place at an institution with the appropriate 
level of neonatal care for the gestational age and the anticipated 
management needs of the neonate.
It is recommended that the placenta is sent for histopathological 
evaluation after delivery. Ideally this should be done in accordance 
with the Amsterdam workshop consensus statement. 358 High-
quality evaluation of the placental pathology is not only likely to 
increase the precision of the diagnosis but also provides information 
on the risks of recurrence.18,359,360
8.4  |  Medical interventions
8.4.1  |  Antenatal corticosteroids
The efficacy of antenatal corticosteroids in cases of FGR has been 
questioned, based on reports of elevated endogenous cortisol levels 
in this population when compared with normally grown fetuses.361-364 
In addition, the unique cardiovascular, hormonal, and metabolic 
changes characteristic of growth-restricted fetuses276,365-369 have 
raised concerns that exposure to exogenous steroids may produce 
potentially harmful cardiovascular and metabolic effects in these 
already compromised fetuses. Indeed, exposure to corticosteroids 
has been shown to result in Doppler changes in growth-restricted 
fetuses such as transient increase in diastolic flow in the umbilical 
artery 370-373 and the middle cerebral artery,374-376 which have been 
attributed to peripheral vasodilatation or an increase in cardiac out-
put and circulatory stress.376,377 Despite this, recent data support 
the efficacy and safety of antenatal corticosteroids in the subgroup 
of SGA fetuses,378,379 which should be administered when delivery 
is anticipated, ideally within 1–7 days before birth.380 When admin-
istered in cases of severe FGR with late Doppler changes, an inpa-
tient setting is advised where the fetus can be closely monitored. 
Finally, it is important to recognize that the “improvement” in um-
bilical artery Doppler that is often seen following administration of 
antenatal corticosteroids is transient, and is thought to be the result 
of vasodilation of the fetoplacental arterial tree and increased fetal 
cardiac output rather than a true decrease in placental resistance.381 
Therefore, these transient changes should not be interpreted as an 
improvement in fetal status and should not affect the management 
plan. Of note, the absence of any change in end-diastolic flow in re-
sponse to antenatal corticosteroids is a concern and predicts subse-
quent fetal deterioration.372
8.4.2  |  Magnesium sulfate for neuroprotection
Administration of magnesium sulfate to women at risk of preterm 
birth has been shown to have a neuroprotective role, with a decrease 
in the risk of perinatal mortality, cerebral palsy, and gross motor 
dysfunction.382,383 Possible mechanisms thought to be involved 
in the beneficial effects of magnesium sulfate include reducing 
intracellular calcium levels, stabilizing blood pressure, normalizing 
cerebral blood flow, blocking the effects of excitatory neurotrans-
mitters such as glutamate, and antioxidant and anti-inflammatory 
effects.384,385 However, the optimal protocol for the administration 
of magnesium sulfate for the purpose of neuroprotection remains 
unclear and available protocols vary with regard to the timing of 
administration, upper gestational age limit, dose, duration, and need 
for repeat doses.386-389
The observation that term FGR infants have higher cord blood 
magnesium levels compared with normally grown infants raises the 
theoretical concern that maternal administration of magnesium sul-
fate in cases of FGR might result in toxic magnesium levels in the 
fetus.390,391 However, there are currently no data on the efficacy and 
safety of magnesium sulfate in FGR fetuses that can support or refute 
these theoretical concerns. Therefore, there is currently no evidence 
in favor or against recommending administration of magnesium sul-
fate for neuroprotection in women at risk of preterm birth with sus-
pected FGR.379 We believe that, at the current time, it is reasonable to 
extrapolate the efficacy of magnesium sulfate to specific subgroups 
of pregnancies, including those complicated by FGR, especially given 
that FGR is an independent risk factor for cerebral palsy.
8.4.3  |  Treatments under investigation
Several novel therapies aiming to improve poor placentation and 
uterine blood flow are being explored, some of which are described 
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below. However, there are currently no proven treatments for FGR, 
and any of the therapies currently under investigation should be 
evaluated only in an appropriately regulated research setting.392
Phosphodiesterase type-5 inhibitors, such as sildenafil citrate, 
potentiate nitric oxide availability, lead to vasodilatation,393,394 and 
can improve umbilical artery and middle cerebral artery Doppler.395 
However, in the recently published STRIDER trial, which randomized 
135 women with early-onset FGR to 25 mg sildenafil three times 
daily or placebo, sildenafil did not prolong pregnancy or improve 
pregnancy outcomes.396 More recently, a similar randomized trial 
was halted prematurely due to lack of benefit along with concerns 
that sildenafil may cause neonatal pulmonary hypertension.397
Another approach is to target the uteroplacental circulation with 
maternal vascular endothelial growth factor gene therapy, thereby 
improving local vasodilatation and angiogenesis.392 Clinically, vector 
delivery into the uterine arteries can be achieved with intervention 
radiology. This approach is currently being investigated in the ongo-
ing EVERREST trial.398 Protein pump inhibitors have been shown in 
vitro to decrease sFlt-1 and soluble endoglin and improve markers 
of endothelial dysfunction. However, in a recent randomized trial 
involving 120 women with preterm pre-eclampsia, esomeprazole did 
not improve pregnancy outcomes.399 Pravastatin has been shown 
to have anti-inflammatory, antioxidant, and proangiogenic proper-
ties.400,401 However, in a recently published randomized trial of 94 
women with early-onset pre-eclampsia, the administration of 40 mg 
pravastatin daily did not lower maternal sFlt-1 levels or prolong preg-
nancy when compared with placebo.402 Other novel potential thera-
pies include nanoparticles and microRNAs that deliver drugs locally 
to the uterine arterial endothelium or trophoblasts, to improve uter-
ine blood flow and placental function.
8.5  |  Recommendations






1. Fetal movement counting is a simple and inexpensive tool that may decrease the risk of stillbirth in 
pregnancies with FGR in both high- and low-resource settings.
⊕⊕○○ Strong
2. Surveillance in pregnancies with FGR should follow a uniform protocol that is based on a combination 
of biophysical (cardiotocogram/nonstress test [CTG/NST], computerized fetal heart rate monitoring 
[cCTG], biophysical profile) and cardiovascular (umbilical artery and middle cerebral artery, with or 
without ductus venosus Doppler) parameters along with predetermined thresholds for delivery.
LRS  In low-resource settings, the combination of CTG/NST and umbilical artery Doppler provides 
sufficient accuracy for the detection of fetal deterioration.
⊕⊕⊕○ Strong
3. In late-onset FGR, middle cerebral artery Doppler and the cerebroplacental ratio can provide additional 
information on fetal deterioration and should be included as part of the Doppler assessment.
LRS  In cases where middle cerebral artery Doppler is not available, twice weekly CTG/NST 
monitoring in cases of late FGR with normal umbilical artery Doppler provides a similar safety net as 
middle cerebral artery Doppler.
⊕⊕○○ Strong
4. Absolute indications for delivery irrespective of gestational age include biophysical profile or CTG/NST 
abnormalities (reduced variability and/or repetitive late decelerations), or severe pre-eclampsia with 
uncontrolled hypertension, HELLP syndrome, or other types of end organ damage.
⊕⊕⊕⊕ Strong
5. In cases of isolated mild SGA (estimated fetal weight at 3rd–9th percentile) with no additional 
abnormalities (i.e. normal fluid and Doppler studies), delivery may be deferred until 37–39 weeks. 
Until then, monitoring should include umbilical artery and middle cerebral artery Doppler at 
an interval of 1–2 weeks. For mild SGA at term (≥37 weeks), monitoring with CTG/NST and/or 
biophysical profile 1–2 times per week may be considered in addition to Doppler studies.
⊕⊕⊕○ Strong
6. In cases of isolated severe SGA (estimated fetal weight <3rd percentile) with no additional 
abnormalities, delivery may be deferred until 36–38 weeks. Until then, monitoring should include 
umbilical artery and middle cerebral artery Doppler 1–2 times per week. For severe SGA at term 
(≥37 weeks) monitoring with CTG/NST and/or biophysical profile 1–2 times per week may be 
considered in addition to Doppler studies.
⊕⊕⊕○ Strong
7. In cases of FGR with early Doppler changes or mild associated abnormalities (oligohydramnios, 
suboptimal interval growth, pre-eclampsia), delivery may be deferred until 34–37 weeks. Until then, 
monitoring should include CTG/NST and/or biophysical profile twice per week and Doppler 1–2 times 
per week.
⊕⊕○○ Strong
8. In cases of FGR with umbilical artery absent end-diastolic velocity (AEDV), delivery may be deferred 
until 32 weeks. Until then, inpatient monitoring is recommended with CTG/NST and/or biophysical 
profile 1–2 times per day and Doppler 3 times per week.
⊕⊕○○ Strong
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9. In cases of FGR with umbilical artery reversed end-diastolic velocity (REDV), delivery may be deferred 
until 30 weeks. Until then, inpatient monitoring is recommended with CTG/NST and/or biophysical 
profile twice per day and daily Doppler.
⊕⊕○○ Strong
10. In cases of FGR with abnormal ductus venosus Doppler, delivery may be recommended as early as 
26–30 weeks. Timing should be individualized based on local neonatal outcomes. Intensive inpatient 
monitoring is recommended with CTG/NST and/or biophysical profile twice per day and daily 
Doppler. Before 26 weeks, careful and shared decision making with the parents and neonatology 
team is recommended.
⊕⊕○○ Weak
11. FGR alone is not an indication for cesarean section. Primary cesarean section may be considered in 
cases of early-onset FGR with late umbilical artery (AEDV/REDV) or ductus venosus Doppler changes, 
abnormal CTG/NST or biophysical profile, maternal indications such as severe pre-eclampsia, or 
contraindications for vaginal birth. In the absence of these conditions, induction of labor should be 
preferred.
⊕⊕○○ Strong
12. Delivery of FGR fetuses should ideally take place at centers with the appropriate level of neonatal 
care for the gestational age and with the ability to perform urgent cesarean section if needed. During 
labor, continuous fetal heart rate monitoring is recommended.
⊕⊕⊕⊕ Strong
13. The placenta should be sent for histopathological examination where available as it may provide 
useful information for counselling regarding future pregnancies.
⊕⊕○○ Strong
14. The administration of antenatal corticosteroids in FGR pregnancies should follow the same protocol 
used in pregnancies not affected by FGR. Close fetal monitoring should be considered when antenatal 
corticosteroids are administered in fetuses with severe FGR with late Doppler changes.
⊕⊕⊕○ Strong
15. The administration of magnesium sulfate for neuroprotection in preterm FGR pregnancies should 
follow the same protocol used in pregnancies not affected by FGR.
⊕⊕○○ Strong
16. There are currently no proven treatments for FGR. ⊕⊕⊕○ Strong
 Cont.
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9  |  POSTPARTUM A SSESSMENT AND 
COUNSELLING FOR FUTURE PREGNANCIES
9.1  |  Infant follow-up
Growth-restricted infants are at increased risk of both immediate 
and long-term complications, and therefore require closer follow-up 
than normally grown infants in the first years of life.
Growth-restricted infants have lower survival rates compared 
with those appropriate for gestational age.403 Although this may 
be attributed in part to prematurity that is often associated with 
FGR, birth weight has been shown to be an independent prog-
nostic factor for neonatal mortality, irrespective of gestational 
age.404 In a population-based cohort study, the mortality rate 
of term FGR neonates was approximately five-fold higher com-
pared with appropriate for gestational age neonates (0.3% vs 
0.06%).405
FGR can affect postnatal growth. In cases of mild FGR, in-
fants tend to achieve normal height during the first year of 
life.406 In cases affected by severe FGR, however, height in the 
late teens is lower than those born appropriate for gestational 
age (169.9 ± 1.5 vs 175.4 ± 0.8 cm; P < 0.0001 for boys; and 
159.4 ± 1.3 vs 163.1 ± 0.8 cm; P < 0.0005 for girls).407
FGR infants are also at increased risk of adverse long-term neu-
rodevelopmental outcomes. A systematic review of this topic found 
that FGR infants are at higher risk of poor neurodevelopmental out-
comes measured up to 3 years of age; however, high levels of hetero-
geneity in primary outcomes were reported in the studies included 
in the review.12 Of note, adverse neurodevelopmental outcomes 
may at least partly be related to coexisting increased prematurity 
rates.408
In line with the developmental origins of health and disease 
hypothesis, FGR has been associated, in both animal and human 
studies, with an increased risk of future noncommunicable diseases 
including obesity, diabetes, hypertension, and cardiovascular dis-
ease.409-411 The risk is especially high in those infants who experi-
ence rapid catch-up growth in the first few years of life.412,413 The 
mechanisms underlying these associations are not entirely clear. 
However, fetal programming by means of epigenetic changes as well 
as direct organ damage are thought to play a role.414 Ongoing studies 
are investigating the optimal follow-up and prevention strategies to 
decrease the risk of these complications.415,416
9.2  |  Maternal follow-up
It is well established that women with a history of pregnancy com-
plicated by FGR or other placenta-mediated complications such as 
pre-eclampsia are at an increased risk of future cardiovascular dis-
ease, especially in the presence of early-onset disease. In a popula-
tion-based study that included more than 100 000 pregnancies and 
provided maternal follow-up for 15–19 years, delivery of a low birth 
weight infant was associated with increased maternal risk of ischemic 
heart disease or death (aHR 1.9; 95% CI, 1.5–2.4).417 Moreover, a 
combination of FGR, pre-eclampsia, and preterm delivery amplified 
the risk of disease seven-fold. For a detailed review of the evidence 
supporting these associations, their underlying mechanisms, and 
recommendations on maternal follow-up and prevention strategies, 
please refer to the recently published FIGO postpregnancy initiative 
on long-term maternal implications of pregnancy complications and 
follow-up considerations.4
9.3  |  Counselling regarding future pregnancies
The most frequent and relevant question that care providers are 
being asked by couples whose prior pregnancy was complicated 
by FGR relates to the likelihood of a similar complication in subse-
quent pregnancies. The answer to this question is often difficult and 
depends on several factors, namely the underlying etiology, severity 
and timing of onset, and the presence or absence of modifiable risk 
factors (e.g. maternal medical conditions or smoking). In cases of pla-
centa-mediated FGR, the results of the placental histopathological 
examination may provide valuable information that can assist care 
providers in counselling patients regarding the risk of recurrence, 
role of further investigation, and potential preventive interventions 
in subsequent pregnancies.
9.3.1  |  Risk of recurrence based on 
severity and onset
Most of the data on the risk of recurrence of placenta-mediated 
complications come from studies evaluating hypertensive com-
plications of pregnancy. In a recent individual patient data 
meta-analysis of 22 studies, the overall risk of recurrence of hyper-
tensive complications was 21%, and was higher in women who ex-
perienced early-onset hypertensive complications.418 Data on the 
recurrence of FGR are limited.419-422 In a population-based study, 
the overall recurrence rate of FGR in women who gave birth to an 
infant with a birth weight below the 10th percentile was 24%, com-
pared with 6% in women without a history of FGR (OR 3.9; 95% CI, 
3.7–4.0). The risk of recurrence was related to the severity of FGR, 
and was nearly six-fold when the infant birth weight was below 
the 5th percentile (OR 5.7; 95% CI, 5.4–6.0).423 Thus, couples 
with FGR in the first pregnancy can be reassured that the overall 
chance of recurrence in subsequent pregnancies is less than 25%. 
However, interpretation of the data is limited by the lack of distinc-
tion between constitutionally SGA infants and infants who were 
truly growth restricted, as much of the association described in 
that study may be driven by the recurrence of constitutional SGA. 
Therefore, counselling regarding the risk of recurrence should be 
further refined based on the risk factors of the individual patient, 
severity of FGR as reflected by timing of onset and Doppler find-
ings, the co-presence of pre-eclampsia, and placental histopatho-
logical findings.
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9.3.2  |  Risk of recurrence based on placental 
histopathology
The results of the placental histopathological examination are 
important for two main reasons. First, they may assist care provid-
ers in counselling couples regarding the most likely etiology of FGR, 
especially when the clinical presentation and Doppler findings were 
inconclusive. Second, placental findings may provide valuable infor-
mation regarding the risk of recurrence, as certain types of placental 
pathologies are associated with a relatively high recurrence rate. The 
main types of placental pathologies, the clinical phenotypes associ-
ated with these pathologies, and their estimated risks of recurrence 
are summarized in Table 2.424-426
9.3.3  |  Role of thrombophilia screening
Whether women who experienced placenta-mediated pregnancy 
complications should be screened for antiphospholipid syndrome 
is a matter of debate. Although the consensus criteria for antiphos-
pholipid syndrome include premature birth before 34 weeks for 
severe pre-eclampsia or features consistent with placental insuf-
ficiency including birth weight below the 10th percentile,427 the 
association of antiphospholipid (aPL) antibodies with these condi-
tions is relatively weak and conflicting, especially for FGR.428-430 In 
addition, although some care providers recommend treatment with 
LMWH during pregnancy to women with aPL syndrome and previ-
ous preterm birth for placenta-mediated complications, this prac-
tice is mostly extrapolated from women with aPL syndrome and 
recurrent pregnancy loss, where there is some evidence in favor 
of LMWH.431-433 However, the only trial on LMWH in women with 
aPL syndrome and prior placenta-related complications (FRUIT 
trial) found no evidence that LMWH improves outcomes in these 
cases.434 Given the above, there is insufficient evidence to justify 
routine screening for aPL antibodies in women with prior FGR.435 
However, screening for aPL antibodies is recommended in women 
with a history of thromboembolism or recurrent pregnancy loss 
(or ≥1 late fetal loss), and may be considered in selected cases of 
women with a history of severe FGR associated with severe early-
onset pre-eclampsia, when placental examination shows features 
of severe maternal vascular malperfusion, especially central or mul-
tiple areas of villous infarction that are due to multiple spiral artery 
thromboses.
Management of women already diagnosed with antiphospho-
lipid syndrome based on a history of placenta-mediated complica-
tions is also under debate. Based on the evidence from the FRUIT 
trial described above, some only recommend treatment with aspi-
rin in this setting,436 while others recommend either surveillance or 
LMWH during the antepartum and postpartum periods.437 Based on 
available evidence we only recommend treatment with aspirin, and 
suggest that LMWH be considered only in selected cases, such as 
for women who have experienced recurrent complications despite 
aspirin treatment (aspirin failure).
The findings are clearer for inherited thrombophilias. Most pro-
spective studies found no significant association between inherited 
thrombophilia and placenta-mediated complications.438-443 
Furthermore, the TIPPS and FRUIT trials found no benefit of LMWH 
in women with thrombophilia and a history of placenta-mediated 
pregnancy complications.444,445 These findings were confirmed by 
a recent individual patient data meta-analysis that found no benefit 
of LMWH in decreasing the risk of recurrence of placenta-mediated 
complications, including in women with thrombophilia.140 Therefore, 
there is no indication for routine screening for inherited thrombo-
philia in women with prior FGR.446,447
9.3.4  |  Preconception counselling and 
management of future pregnancies
Given the considerable risk of recurrence of FGR, efforts should be 
made to decrease this risk in future pregnancies.448 Modifiable risk 
factors for FGR such as smoking or poor nutritional status should be 
identified as early as possible and managed accordingly, as discussed 
in section 5.5.1.
There is some evidence that administration of aspirin can reduce 
the risk of FGR. However, as described in section 5.5.2 most available 
data focused on the prevention of pre-eclampsia as the primary out-
come in women at high risk of pre-eclampsia, with the prevention of 
FGR being considered a secondary outcome. Data on the prevention 
of recurrence of FGR in women with a history of FGR are limited.449 
Therefore, some recommend that aspirin should be considered in 
women with past FGR only if they have risk factors for pre-eclampsia 
at the time of the next pregnancy.450 However, we believe that given 
the safety of aspirin and the overlap in pathogenesis of pre-eclampsia 
and FGR, it is reasonable to recommend aspirin to women with a his-
tory of placenta-mediated FGR in the previous pregnancy, using the 
same regimen of aspirin used for the prevention of pre-eclampsia. This 
recommendation is shared by most professional societies.134
Data on the role of LMWH to prevent recurrence of placenta- 
mediated complications including FGR are conflicting, and this topic 
is reviewed in section 5.5.2. Based on available data, LMWH therapy 
should not be used in women with a past history of FGR except in a 
research setting.
Given the association of insufficient gestational weight gain 
with FGR, we recommend monitoring of weight gain and inform-
ing women about their target weight gain range, as described in 
section 5.5.1. Other interventions, such as bed rest or nutritional 
supplements are of unproven benefit and should not be routinely 
offered.451,452 The risk of recurrence can be further stratified in 
early pregnancy by means of prenatal screening with biochemical 
markers (PAPP-A, beta hCG, alpha-fetoprotein, and PlGF) as well 
as by uterine artery Doppler, as described in section 5. Due to the 
increased risk of recurrence, pregnant women with a history of FGR 
in a previous pregnancy should be managed in a high-risk pregnancy 
clinic and should receive closer antenatal surveillance, including 
close monitoring of fetal growth and maternal blood pressure.453
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9.4  |  Recommendations







1. Growth-restricted infants are at an increased risk of short- and long-term morbidity and should be 
followed postnatally more closely than normally grown infants.
⊕⊕○○ Strong
2. Women with a history of placenta-mediated pregnancy complications including FGR are at an increased 
risk of future cardiovascular morbidity and should be advised regarding preventive strategies as 
reviewed in detail in the FIGO postpregnancy initiative on long-term maternal implications of 
pregnancy complications and follow-up considerations.4
⊕⊕⊕○ Strong
3. Women with a history of FGR should be counselled regarding the risk of recurrence based on timing of 
onset, severity of FGR, and placental histopathological findings.
⊕⊕○○ Strong
4. Women with a history of FGR should not be routinely screened for antiphospholipid antibodies in the 
absence of a history of thromboembolism or pregnancy loss.
⊕⊕⊕○ Strong
5. There is no role for screening for hereditary thrombophilias in women with a history of FGR. ⊕⊕⊕○ Strong
6. The following preventive interventions are recommended in women with a history of placenta-mediated 
FGR and those at risk of pre-eclampsia: smoking cessation, aspirin at a dose of 100–150 mg taken in 
the evening starting at 12–16 weeks.
⊕⊕○○ Strong
7. Low-molecular-weight heparin is not recommended for the prevention of FGR in women with a history 
of placenta-mediated FGR.
⊕⊕⊕○ Strong
8. In women with antiphospholipid syndrome and a history of placenta-mediated FGR, low-molecular-
weight heparin may be considered in selected cases, such as in women who have experienced 
recurrent complications despite aspirin treatment (aspirin failure).
⊕⊕○○ Weak
9. Women with a history of FGR should undergo close surveillance of fetal growth starting at 
24–28 weeks.
⊕⊕⊕○ Strong
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10  |  SUMMARY AND FUTURE RESE ARCH 
DIREC TIONS
FGR is an important cause of stillbirth, neonatal mortality, and short- 
and long-term neonatal morbidity. Early prediction and preventive 
strategies, timely diagnosis, and management using a standardized 
protocol to determine the proper monitoring and timing of delivery 
can decrease the risk of stillbirth and improve perinatal outcomes in 
pregnancies complicated by FGR.
Future research should focus on the development of new fetal 
assessment tools that may improve the accuracy of the prediction 
of fetal deterioration and thus further optimize timing of delivery 
of FGR fetuses, as well as on novel treatments that may improve 
placental function in cases of placenta-mediated FGR and thereby 
deferring delivery in cases of early-onset FGR.
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